

Tuesday, February 06, 2018

Volume 49 No. 2



NOTICE – Items in this issue will be listed online weekly and printed monthly.

### ACM RESEARCH INC

Earnings, 9 mos. to Sep 30 (Consol. – \$000):

	2017	2016
Total Revenues	19,314	13,026
Cost & expenses	22,379	13,801
Operating income	(3,065)	(775)
Interest income	7	13
Interest expense	197	118
Other income (expense), net	(511)	471
Net before taxes	(3,766)	(409)
Income taxes	471	59
Net income	(4,237)	(468)
Earnings common share		
Primary	\$(0.72)	\$(0.09)
Fully Diluted	\$(0.72)	\$(0.09)
Common Shares:		
Full Diluted	5,148	2,077
Year-end	7,151	

gains (losses)	(30,705)	(35,716)	(20,130)
Realized gains on fixed income investment	1,673	2,880	3,309
Realized losses on fixed income investment	(725)	(985)	(354)
Other interest & other income (expense), net	83	29	22,325
Interest expense	74,402	70,442	64,184
Investment gains (losses), net	7,553	(1,570)	961
Total non-operating income (expense), net	(30,454)	(58,464)	(29,314)
Income before income taxes - domestic	1,056,156	805,749	589,371
Income before income taxes - foreign	1,081,485	629,389	284,410
Income before income taxes	2,137,641	1,435,138	873,781
Current provision for (benefit of) income taxes - U.S. federal	298,802	94,396	204,834
Current provision for (benefit of) income taxes-foreign	60,962	59,749	52,125
Current provision for (benefit of) income taxes-state & local	33,578	15,222	(14,975)
Total current provision for (benefit of) income taxes	393,342	169,367	241,984
Deferred provision for (benefit of) income taxes-U.S. federal	48,905	33,924	(31,011)
Deferred provision for (benefit of) income taxes-foreign	(4,242)	(2,751)	(9,368)
Deferred provision for (benefit of) income taxes-state & local	5,682	(9,287)	(25,511)
Total deferred provision for (benefit of) income taxes	50,345	21,886	(65,890)
Tax expense attributable to employee stock plans		75,103	68,136
Provision for (benefit of) income taxes	443,687	266,356	244,230
Net income (loss)	1,693,954	1,168,782	629,551
Weighted average shares outstanding-basic	493,632	498,345	498,764
Weighted average shares outstanding-diluted	501,123	504,299	507,164

Year end shares outstanding	491,262	494,254	497,809
Net income (loss) per share-basic	\$3.43	\$2.35	\$1.26
Net income (loss) per share-diluted	\$3.38	\$2.32	\$1.24
Total number of employees	17,973	15,706	13,893
Number of common stockholders	1,091	1,125	1,215
Foreign currency translation adjustments	90,287	(19,783)	(123,065)

Reclassified to conform with 2017 presentation; As is; As of January 12, 2018; As of January 13, 2017; As of January 15, 2016

### ADAMAS PHARMACEUTICALS INC

**Secondary Offering** On Jan. 22, 2018, Co. announced the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a price to the public of \$41.50 per share. The aggregate gross proceeds from this offering are expected to be \$124,500,000, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Co. Co. also granted the underwriters a 30-day option to acquire up to an additional 450,000 shares from Co. The offering is expected to close on Jan. 26, 2018, subject to customary closing conditions.

### ADVANTAGE TECHNOLOGIES GROUP, INC.

**Annual Meeting Development** On Jan. 22, 2018, Co. scheduled its annual Meeting of Shareholders for Wednesday, Mar. 7, 2018, at 9:00 A.M., at Co.'s Corporate Office, 1221 East Houston Broken Arrow, OK 74012.

### ADOBE SYSTEMS INC

#### Annual Report

#### Consolidated Income Statement, Years Ended (\$000):

	12/01/17	12/02/16 (revised)	11/27/15 (revised)
Subscription	6,133,869	4,584,833	3,223,904
Products revenue	706,767	800,498	1,125,146
Services & support revenue	460,869	469,099	446,461
Total revenue	7,301,505	5,854,430	4,795,511
Cost of revenue-subscription	623,048	461,860	409,194
Cost of revenue-products	57,082	68,917	90,035
Cost of revenue-services & support	330,361	289,131	245,088
Total cost of revenue	1,010,491	819,908	744,317
Gross profit	6,291,014	5,034,522	4,051,194
Research & development expenses	1,224,059	975,987	862,730
Sales & marketing expenses	2,197,592	1,910,197	1,683,242
General & administrative expenses	624,706	576,202	533,478
Amortization of purchased intangibles	76,562	78,534	68,649
Total operating expenses	4,122,919	3,540,920	3,148,099
Operating income	2,168,095	1,493,602	903,095
Interest income	66,069	47,340	28,759
Foreign exchange			

#### Consolidated Balance Sheet, Years Ended (\$000):

	12/01/17	12/02/16 (revised)
Cash	280,488	208,635
Corporate bonds & commercial paper		1,249
Money market mutual funds	2,006,741	782,210
Municipal securities		1,301
Time deposits	18,843	17,920
Cash & cash equivalents	2,306,072	1,011,315
Asset-backed securities	98,001	110,914
Corporate bonds & commercial paper	2,454,260	2,458,350
Foreign government securities	2,388	
Municipal securities	21,065	134,222
U.S. agency securities		39,580
U.S. treasury securities	937,988	1,006,919
Short-term investments	3,513,702	3,749,985
Trade receivables, gross	1,227,119	839,247
Allowances for doubtful accounts	9,151	6,214
Trade receivables, net	1,217,968	833,033
Prepaid expenses & other current assets	210,071	245,441
Total current assets	7,247,813	5,839,774
Computers & equipment	1,128,264	1,051,937
Furniture & fixtures	115,273	94,243
Capital projects in-progress	5,575	7,648
Leasehold improvements	120,165	110,414
Land	77,723	77,340
Buildings	490,665	382,364
Buildings improvements	265,829	202,266
Property & equipment, gross	2,203,494	1,926,212
Less accumulated depreciation & amortization	1,266,518	1,109,948
Property & equipment, net	936,976	816,264
Goodwill	5,821,561	5,406,474
Purchased & other intangibles, net	385,658	414,405
Investment in lease receivable		80,439
Other assets	143,548	139,890
Total assets	14,535,556	12,697,246
Trade payables	113,538	88,024
Accrued compensation & benefits	417,742	339,487

Accrued media costs .....	134,525	5,144
Sales & marketing allowances .....	47,389	55,681
Accrued corporate marketing .....	72,087	55,218
Taxes payable .....	49,550	43,113
Royalties payable .....	46,411	25,089
Accrued interest expense .....	25,594	25,805
Other accrued expenses .....	200,475	190,093
Income taxes payable .....	14,196	38,362
Deferred revenue .....	2,405,950	1,945,619
Total current liabilities .....	3,527,457	2,811,635
Notes .....	1,881,421	1,892,200
Deferred revenue .....	88,592	69,131
Income taxes payable .....	173,088	184,381
Deferred income taxes .....	279,941	217,660
Other liabilities .....	125,188	97,404
Total liabilities .....	6,075,687	5,272,411
Common stock .....	61	61
Additional paid-in capital .....	5,082,195	4,616,331
Retained earnings .....	9,573,870	8,114,517
Unrealized gains on available-for-sale securities .....	2,704	3,499
Unrealized losses on available-for-sale securities .....	(14,220)	(11,565)
Net unrealized gains on derivative instruments designated as hedging instruments .....	(3,367)	21,689
Cumulative foreign currency translation adjustments .....	(96,938)	(187,225)
Accumulated other comprehensive income (loss) .....	(111,821)	(173,602)
Treasury stock, net of reissuances .....	6,084,436	5,132,472
Total stockholders' equity (deficit) .....	8,459,869	7,424,835

□ Reclassified to conform with 2017 presentation

#### Recent Dividends:

##### 1. Adobe Systems Inc common.

No dividends paid.

##### Annual Dividends:

##### 1. Adobe Systems Inc common.

No dividends paid.

#### AERIE PHARMACEUTICALS INC

**Offering** On Jan. 23, 2018, Co. announced that it has priced its registered underwritten public offering of \$75,000,000 of shares of its common stock. Total gross proceeds from the offering are expected to be \$75,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on or about Jan. 26, 2018, subject to the satisfaction of customary closing conditions. Cantor Fitzgerald & Co. is acting as the sole bookrunner for the offering. Mizuho Securities USA LLC and H.C. Wainwright & Co., LLC are acting as co-managers for the offering. The underwriters may offer the shares of common stock from time to time to purchasers directly or through agents, or through brokers in brokerage transactions on The Nasdaq Global Market, or to dealers in negotiated transactions, or in a combination of such methods of sale or otherwise, at a fixed price or prices, which may be changed, or at market prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices. The closing price of Aeries common stock on Jan. 23, 2018 was \$61.00 per share.

#### AGIOS PHARMACEUTICALS INC

**Secondary Offering** On Jan. 17, 2018, Co. announced that it has priced an underwritten public offering of 7,089,553 shares of common stock at a price to the public of \$67.00 per share, before underwriting discounts, which would result in aggregate gross proceeds of approximately \$475,000,000. All of the shares in the offering are to be sold by Co. Co. has also granted the underwriters a 30-day option to purchase from it up to an additional 15% of the shares of common stock offered in the public offering on the same terms and conditions. Closing of the offering is expected to occur on or about Jan. 23, 2018, subject to customary closing conditions.

#### ALLIED MOTION TECHNOLOGIES INC

**Acquisition Completed** On Jan. 19, 2018, Co. purchased substantially all of the operating assets associated with the original equipment ("OE") steering business of Maval Industries, LLC. Terms of the transaction were not disclosed.

#### ANALOG DEVICES INC

**Annual Meeting Development** On Jan. 26, 2018, Co. scheduled its annual Meeting of Shareholders for Wednesday, Mar. 14, 2018, at 9:00 a.m. local time, at Co.'s offices located at 125 Summer Street, Boston, MA 02110.

#### ARROWHEAD PHARMACEUTICALS INC

**Secondary Offering** On Jan. 17, 2018, Co. announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock, offered at a price of \$5.25 per share, before underwriting discounts. The offering is expected to close on or about Jan. 22, 2018, subject to customary closing conditions. In addition, Arrowhead has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the public offering price, less the underwriting discount. Jefferies LLC and Barclays Capital Inc. are acting as bookrunning managers for the offering. Cantor Fitzgerald & Co. is acting as passive joint bookrunner for the offering and Chardan and B. Riley FBR, Inc. are acting as co-managers for the offering.

#### ATHENEX INC

**Secondary Offering** On Jan. 22, 2018, Co. announced an underwritten public offering of 4,300,000 shares of its common stock, subject to market conditions and other factors. In addition, Co. intends to grant the underwriters a 30-day option to purchase up to an additional 645,000 shares of common stock at the public offering price. Co.'s common stock is traded on The Nasdaq Global Select Market under the ticker symbol "ATNX."

#### AUDENTENS THERAPEUTICS INC

**Offering** On Jan. 23, 2018, Co. announced the pricing of its underwritten public offering of 5,750,000 shares of its common stock at a price to the public of \$35.00 per share before underwriting discounts and commission. The gross proceeds to Co. from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by Co., are expected to be approximately \$201,000,000. In addition, Co. has granted the underwriters a 30-day option to purchase up to an additional 862,500 shares of common stock. The offering is expected to close on Jan. 29, 2018, subject to customary closing conditions.

#### AVEXIS INC

**Secondary Offering** On Jan. 16, 2018, Co. announced the pricing of an underwritten public offering of 3,921,600 shares of its common stock at a public offering price of \$102.00 per share, before underwriting discounts and commissions. The net proceeds to Co. from the offering, after deducting the underwriting discounts and commissions and estimated offering expenses payable by Co., are expected to be approximately \$375,500,000. The offering is expected to close on or about Jan. 19, 2018, subject to customary closing conditions. In addition, Co. has granted the underwriters a 30-day option to purchase up to an additional 588,240 shares of common stock at the public offering price, less the underwriting discounts and commissions.

#### BIOCRUST PHARMACEUTICALS INC

**Merger Development** On Jan. 22, 2018, Co. and Idera Pharmaceuticals, Inc. ("Idera") announced that they have signed a definitive merger agreement to form a new enterprise focused on the development and commercialization of medicines to serve more patients suffering from rare diseases. The combined company will be renamed upon closing and will be led by Vincent Milano, CEO of Idera, who will also serve as a member of the Board. Co.'s Chairman, Robert Ingram, will be Chairman of the Board of the combined company and Co.'s CEO Jon P. Stonehouse will serve as a member of the Board of Directors. Terms of the merger were not disclosed.

#### BIOERATIV INC

**Merger Development** On Jan. 21, 2018, Co. entered into an Agreement and Plan of Merger (the "Merger Agreement") with Sanofi ("Parent"), and Blink Acquisition Corp. ("Merger Sub"), an indirect wholly-owned subsidiary of Parent. The Boards of Directors of both Co. and Parent have unanimously approved the Merger Agreement. Pursuant to the Merger Agreement, upon the terms and subject to the conditions thereof, Merger Sub will commence a tender offer (the "Offer") no later than 15 business days after the date of the Merger Agreement, to acquire all of the outstanding shares of common stock of Co., par value \$0.001 per share (the "Shares"), at a purchase price of \$105.00 per Share in cash, net of applicable withholding taxes and without interest (the "Offer Price"). As soon as practicable following the consummation of the Offer and subject to the satisfaction or waiver of certain tender offer and other conditions set forth in the Merger Agreement, Merger Sub will be merged with and into Bioerativ (the "Merger"), with Co. surviving the Merger as an indirect wholly-

owned subsidiary of Parent (the "Surviving Corporation"). The Merger will be governed by Section 251(h) of the DGCL and effected without a vote of Co. stockholders. As a result of the Merger, each Share (other than any Shares (i) owned by Parent, Merger Sub or any other direct or indirect wholly-owned subsidiary of Parent immediately prior to the Effective Time (as defined below) (other than Shares tendered and accepted for payment by Merger Sub in connection with the Offer), (ii) owned by Co. or held in Co.'s treasury immediately prior to the Effective Time, (iii) owned by any direct or indirect wholly-owned Subsidiary of Co. immediately prior to the Effective Time or (iv) issued and outstanding immediately prior to the Effective Time and held by a holder who is entitled to demand appraisal and who has properly exercised and perfected a demand for appraisal of such Shares in accordance with Section 262 of the DGCL and, as of the Effective Time, has neither effectively withdrawn nor lost such holder's right to appraisal and payment under the DGCL with respect to such Shares) will (x) be converted automatically into the right to receive the Offer Price in cash, net of applicable withholding taxes and without interest and (y) cease to be outstanding and will automatically be cancelled and cease to exist and each holder of a certificate representing any such Shares will have only the right to receive the Offer Price in accordance with the Merger Agreement. The Merger Agreement also provides that each Co. stock option and Co. restricted stock unit (collectively, "Co.'s Equity Awards") that is outstanding as of immediately prior to the consummation of the Offer will accelerate and become fully vested and will be canceled and converted into the right to receive the Offer Price (less the applicable exercise price in the case of Co. stock options) in cash (net of applicable withholding taxes and without interest) payable in respect of each Share subject to such Co.'s Equity Award, except that the cash payment with respect to any Co. restricted stock unit granted after the date of the Merger Agreement to employees who are not executive officers will not be vested, and instead will become vested and payable on Dec. 31, 2018, subject to the employee's continued employment with Bioeativ or its affiliates, or upon any earlier termination without cause or constructive termination under the applicable severance plan. In addition, pursuant to the Merger Agreement, Co. is required, among other things, to take all reasonable actions to terminate its 2017 Employee Stock Purchase Plan prior to the date that the Offer, the Merger and the other transactions contemplated by the Merger Agreement (collectively, the "Transactions") close.

#### BLUE BIRD CORP

**Annual Meeting Development** On Jan. 26, 2018, Co. scheduled its annual Meeting of Shareholders for Monday, Mar. 5, 2018, at 9:00 a.m. local time, at the Macon Marriott City Center, 240 Coliseum Drive, Macon, GA 31217.

#### CALLIDUS SOFTWARE INC

**Merger Development** On Jan. 29, 2018, Co., SAP America, Inc., a wholly-owned subsidiary of SAP SE ("Parent"), and Emerson One Acquisition Corp., a wholly-owned subsidiary of Parent ("Merger Sub"), entered into an Agreement and Plan of Merger ("Merger Agreement"). Pursuant to the terms of the Merger Agreement, and subject to the conditions specified in the Merger Agreement, Merger Sub will merge with and into Co., and will become a wholly-owned subsidiary of Parent (the "Merger"). If the Merger is completed, the Co. stockholders will be entitled to receive \$36.00 in cash (the "Merger Consideration") for each share of Co.'s common stock (each, a "Co. Share") owned by them as of the effective time of the Merger (the "Effective Time"). Upon the terms and subject to the conditions set forth in the Merger Agreement, each option to purchase Co. Shares that remains outstanding as of immediately prior to the Effective Time, whether vested or unvested (each, a "Co. Option"), will be cancelled and converted into the right to receive an amount in cash, less applicable withholding taxes, equal to the product of (i) the aggregate number of Co. Shares subject to such Co. Option multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable per share exercise price of such Co. Option. Upon the terms and subject to the conditions set forth in the Merger Agreement, each Co. time-based restricted stock unit award that remains outstanding as of immediately prior to the Effective Time (each, a "Co. RSU") will be treated as follows at the Effective Time: (a) each vested Co. RSU, and each unvested Co. RSU held by a non-employee member of the Board, will be cancelled and converted into the right to receive the Merger Consideration in cash, less applicable withholding taxes, for each Co. Share subject to such Co. RSU. (b) each unvested Co. RSU granted prior to Jan. 29, 2018 that is held by an employee of the Co. shall be cancelled and converted into the right to receive, in cash, less applicable withholding taxes, the Merger Consideration, and such right shall remain subject to the time-based vesting (including any "double-trigger" acceleration) terms that applied with respect to

the applicable Co. RSU immediately prior to the Effective Time. (c) each unvested Co. RSU granted on or after Jan. 29, 2018 shall be cancelled and converted into a cash-settled award of restricted stock units of SAP stock pursuant to an exchange ratio determined based on SAP's trading price at the Effective Time, with the payment amount to be determined based on SAP's trading price at the applicable vesting date, and such award shall remain subject to the time-based vesting (including any "double-trigger" acceleration) terms that applied with respect to the applicable Co. RSU immediately prior to the Effective Time. Upon the terms and subject to the conditions set forth in the Merger Agreement, each Co. performance-based restricted stock unit award that remains outstanding as of immediately prior to the Effective Time (each, a "Co. PSU") will be cancelled and converted into the right to receive, in cash, less applicable withholding taxes, the Merger Consideration for each share that is deemed earned and credited, and such right shall remain subject to the time-based vesting (including any "double-trigger" acceleration) terms that applied with respect to the applicable Co. PSU immediately prior to the Effective Time (each, a "Replacement PSU"). The per share price represents an enterprise value of approximately \$2,400,000,000. The transaction is expected to close in the second quarter of 2018, subject to approval from Co. stockholders, clearances by the relevant regulatory authorities, and other customary closing conditions.

### CASA SYSTEMS INC

#### Annual Report

#### Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2016	2015	2014
Revenue: product	279,223	247,588	194,358
Revenue: services	36,905	24,862	16,920
Total revenues	316,128	272,450	211,278
Cost of revenue: product	89,340	74,349	59,088
Cost of revenue: services	8,477	5,265	5,917
Total cost of revenue	97,817	79,614	65,005
Gross profit	218,311	192,836	146,273
Research & development	49,210	37,155	25,481
Sales & marketing expenses	36,114	36,157	21,409
General & administrative expenses	18,215	16,453	10,346
Total operating expenses	103,539	89,765	57,236
Income (loss) from operations	114,772	103,071	89,037
Interest income	1,208	955	913
Interest expense	902	214	23
Gain (loss) on foreign currency, net	(328)	(3,020)	(3,173)
Other income (expense), net	943	871	(659)
Total other income (expense), net	921	(1,408)	(2,942)
Income before income taxes - United States	106,386	99,972	82,237
Income before income taxes - Foreign	9,307	1,691	3,858
Income (loss) before provision for income taxes	115,693	101,663	86,095
Current federal income taxes	30,876	34,124	30,556
Current state income taxes	1,775	924	3,644
Current foreign income taxes	1,234	331	585
Current income taxes	33,885	35,379	34,785
Deferred federal income taxes	(5,802)	(2,260)	(6,556)
Deferred state income taxes	(979)	346	(1,081)
Deferred foreign income taxes	(79)	277	(761)
Deferred income			

Provision for income taxes	(6,860)	(1,637)	(8,398)
Net income (loss)	88,668	67,921	59,708
Cumulative dividends on convertible preferred stock	5,884	5,884	5,884
Dividends declared on convertible preferred stock	117,903	...	15,485
Undistributed earnings allocated to participating securities	...	34,735	15,052
Net income (loss) attributable to common stockholders	(35,119)	27,302	23,287
Weighted average shares outstanding - basic	32,864	31,740	29,983
Weighted average shares outstanding - diluted	32,864	38,809	32,683
Year end shares outstanding	33,184	31,806	31,673
Net earnings (loss) per share - basic	\$(1.07)	\$0.86	\$0.78
Net earnings (loss) per share - diluted	\$(1.07)	\$0.78	\$0.73
Number of full time employees	604	...	352
Cash dividends per common share	\$2.92	...	\$0.38

#### Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2016	2015
Cash & cash equivalents	329,554	92,496
Marketable securities	14,392	...
Accounts receivable, gross	110,924	91,713
Provision for doubtful accounts	690	768
Accounts receivable, net	110,234	90,945
Raw materials	5,037	4,267
Work in process	103	361
Finished goods - manufactured finished goods	60,866	40,052
Finished goods - deferred inventory costs	4,488	5,680
Valuation adjustment for excess & obsolete inventory	4,519	2,859
Inventory	65,975	47,501
Prepaid expenses & other current assets	7,178	4,173
Prepaid income taxes	39	945
Total current assets	527,372	236,060
Computers & purchased software	9,246	6,570
Leasehold improvements	1,044	905
Furniture & fixtures	1,516	1,416
Machinery & equipment	11,494	8,068
Land	3,091	3,091
Buildings	4,765	4,765
Building improvements	4,724	3,152
Trial systems at customers' sites	6,581	6,028
Total property & equipment, gross	42,461	33,995
Less accumulated depreciation & amortization	16,779	11,667
Property & equipment, net	25,682	22,328
Accounts receivable, net of current portion	6,629	9,839
Deferred tax assets	21,140	14,280
Deferred issuance costs	1,464	...
Other assets	748	590
Total assets	583,035	283,097

Accounts payable	21,704	7,218
Accrued compensation & related taxes	18,475	17,346
Accrued warranty	1,256	993
Dividends & equitable adjustments payable	107,509	383
Accrued customer incentive	15,449	...
Other accrued expenses	6,495	6,632
Accrued expenses & other current liabilities	149,184	25,354
Accrued income taxes	11,823	4,882
Deferred revenues	55,876	35,353
Current portion of long-term debt, net of unamortized debt issuance costs	2,133	272
Total current liabilities	240,720	73,079
Accrued income taxes, net of current portion	463	449
Deferred revenue, net of current portion	18,458	22,109
Term loans	297,000	...
Mortgage loan	7,261	7,553
Non-current portion of principal payment obligations	304,261	7,553
Unamortized debt issuance costs, non-current portion	(6,643)	(30)
Long-term debt, net of current portion & unamortized debt issuance costs	297,618	7,523
Total liabilities	557,259	103,160
Series B convertible preferred stock	1,542	1,542
Series C convertible preferred stock	95,937	95,937
Convertible preferred stock (series A, B & C)	97,479	97,479
Common stock	33	32
Additional paid-in capital	...	14,719
Accumulated other comprehensive income (loss)	(1,739)	(214)
Retained earnings (accumulated deficit)	(69,997)	67,921
Total stockholders' equity (deficit)	(71,703)	82,458

#### Recent Dividends:

##### 1. Casa Systems Inc common.

No dividends paid.

#### Annual Dividends:

##### 1. Casa Systems Inc common.

No dividends paid.

#### CELGENE CORP

**Merger Development** On Jan. 21, 2018, Co. entered into an Agreement and Plan of Merger (the "Merger Agreement") with Juno Therapeutics, Inc. ("Juno"), and Blue Magpie Corp. a wholly-owned subsidiary of Co. ("Purchaser"), pursuant to which, among other things, subject to the terms and conditions of the Merger Agreement, Purchaser will commence a tender offer (the "Offer") for all of the outstanding shares of common stock of Juno, par value \$0.0001 per share (the "Juno Shares"), at a purchase price of \$87.00 per Juno Share, net to the seller in cash, subject to reduction for any applicable withholding taxes (the "Offer Price"). Following the completion of the Offer and subject to the terms and conditions of the Merger Agreement, Purchaser will merge with and into Juno, with Juno surviving as a wholly-owned subsidiary of Co., pursuant to the procedures provided for under Section 251(h) of the Delaware General Corporation Law without any stockholder approvals (the "Merger"). At the effective time of the Merger (the "Effective Time"), each outstanding Juno Share, other than any shares owned by (i) Juno (or held in its treasury), (ii) Co., Purchaser, or any other direct or indirect wholly owned subsidiary of Co., or (iii) any stockholders who are entitled to and who properly exercise and perfect appraisal rights under Delaware law (and have neither withdrawn nor lost their rights), will be automatically converted into the right to receive an amount in cash equal to the Offer Price, without interest. Co.'s

Board of Directors has, by unanimous vote, approved the Merger Agreement, the Merger and the other transactions contemplated by the Merger Agreement. Pursuant to the terms of the Merger Agreement, each outstanding unvested Juno stock option ("Option"), each outstanding award of Juno time-based restricted stock units ("RSUs"), and each outstanding award of Juno time-based restricted stock awards ("RSAs"), (i) if granted twelve (12) months or more prior to the Effective Time, will become vested pursuant to their respective terms or, if greater, with respect to 25% of the total number of Juno Shares subject to such award, (ii) if granted following the date of the Merger Agreement but prior to the Effective Time, will become vested pursuant to their respective terms or, if greater, with respect to 25% of the total number of Juno Shares subject to such award (the "Pre-Closing Non-Performance Awards"), or (iii) if granted less than twelve (12) months prior to the Effective Time (other than the Pre-Closing Non-Performance Awards), will become vested pursuant to their respective terms or, if greater, with respect to that number of Juno Shares subject thereto, such that, following such vesting, the award will be unvested with respect to that number of Juno Shares which would have become vested and resulted in the award being 100% vested had the holder of the award remained continuously employed for an additional twenty-four months following the Effective Time; provided, that, with respect to any awards referred to in subsections (i) and (iii) above, if, as of the 24-month anniversary of the Effective Time, any portion of such awards remains unvested, such unvested portion will become immediately vested on such 24-month anniversary date, provided that the employee has remained employed through such 24-month anniversary date. All such awards that become vested or that are otherwise vested as of immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement) will be cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of Juno Shares subject to such vested award and (ii) the Offer Price (reduced by the applicable exercise price in the case of Juno options). The Merger Agreement provides that Options, RSUs and RSAs that are outstanding immediately prior to the Offer Acceptance Time but unvested after giving effect to the vesting acceleration described above will be assumed by Co. and will be subject to the same terms and conditions (except with respect to the vesting schedule), as applied to each such equity-based award immediately prior to the Effective Time, provided that the number of shares subject to such equity-based awards (and the exercise price in the case of the Options) will be adjusted based on the "Exchange Ratio." The "Exchange Ratio" means an amount equal to the quotient obtained by dividing (i) the Offer Price, by (ii) the volume weighted average price per share of Co.'s common stock on the Nasdaq Stock Market for the fifteen consecutive trading days ending on the complete trading day immediately prior to the Offer Acceptance Time. The Merger Agreement also provides that all Juno performance-based restricted stock units ("PSUs") and all Juno performance-based restricted stock awards ("PSAs") will vest as to 50% of the total number of PSUs or PSAs (as applicable) subject to such awards, and such vested portion will be cancelled and converted into the right to receive an amount in cash equal to the product of (i) such 50% vested portion of the award, and (ii) the Offer Price. The remaining 50% of the PSUs and PSAs will be assumed by Co. and will be subject to the same terms and conditions as were applicable to such awards immediately prior to the Offer Acceptance Time, provided that the number of shares subject to such equity-based awards (and the exercise price in the case of the Options) will be adjusted based on the Exchange Ratio, except that (i) 60% of such remaining award will vest on the one-year anniversary of the Effective Time and (ii) 40% of such remaining award will vest on the earlier of (A) the second anniversary of the Effective Time and (B) the first approval by the FDA of JCAR017.

#### COMMVault SYSTEMS INC

Earnings, 9 mos. to Dec 31(Consol. - \$000):

	2017	2016
Total Revenues	514,478	478,273
Cost & expenses	512,804	471,335
Deprec., depl. & amort.	7,212	6,382
Operating income	(5,538)	556
Interest income	1,560	843
Interest expense	698	724
Other income (expense), net	(281)	(544)
Net before taxes	(4,957)	131
Income taxes	55,282	836
Net income	(60,239)	(705)
Earnings common share		
Primary	\$(1.33)	\$(0.02)
Fully Diluted	\$(1.33)	\$(0.02)
Common Shares:		

	Full Diluted	2017	2016
Year-end	44,785	45,340	44,645
<b>COMPUTER SERVICES, INC.</b>			
Earnings, 9 mos. to Nov 30(Consol. - \$000):			
Total Revenues	186,914	174,591	174,591
Cost & expenses	145,501	136,959	136,959
Operating income	41,413	37,632	37,632
Net before taxes	41,503	37,697	37,697
Income taxes	16,213	14,419	14,419
Net income	25,290	23,278	23,278
Earnings common share			
Primary	\$1.81	\$1.66	\$1.66
Fully Diluted	\$1.81	\$1.66	\$1.66
Common Shares:			
Full Diluted	13,968	14,015	14,015
Year-end	13,956	14,006	14,006

#### CONFORMIS INC

Offering On Jan. 24, 2018, Co. announced the pricing of an underwritten public offering of 13,333,333 shares of its common stock at a public offering price of \$1.50 per share, before underwriting discounts, raising \$20,000,000 in gross proceeds for Co. In addition, Co. has granted the underwriters a 30-day option to purchase up to an additional 2,000,000 shares of common stock. All of the shares in the offering are to be sold by Co.

#### CORIU INTERNATIONAL INC

Annual Meeting Development On Jan. 24, 2018, Co. announced that its Annual Meeting of Stockholders will be held on Mar. 20, 2018 at 1:00 p.m. (Pacific Time) at the offices of Fenwick & West LLP, 801 California Street, Mountain View, CA 94041.

#### DENALI THERAPEUTICS INC

##### Annual Report

##### Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2016	2015
Research & development	75,702	11,571
General & administrative expenses	11,731	5,108
Total operating expenses	87,433	16,679
Interest income (expense), net	781	(109)
Net income (loss)	(86,652)	(16,788)
Weighted average shares outstanding - basic	6,425	3,006
Weighted average shares outstanding - diluted	6,425	3,006
Year end shares outstanding	8,597	4,261
Net earnings (loss) per share - basic	\$(13.49)	\$(5.58)
Net earnings (loss) per share - diluted	\$(13.49)	\$(5.58)
Number of common stockholders	148	...
Number of full time employees	125	...

<sup>1</sup> As of September 30, 2017; <sup>2</sup> As is; <sup>3</sup> Approximately

##### Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2016	2015
Cash & cash equivalents	39,853	30,740
Short-term marketable securities	138,478	...
Prepaid research & development expenses	2,396	1,652
Accrued interest on short-term marketable securities	438	...
Prepaid employee bonuses	234	973
Other prepaid & current assets	556	66
Prepaid expenses & other current assets	3,624	2,691
Total current assets	181,955	33,431
Long-term marketable securities	72,580	...

Lab equipment	8,868	3,034
Leasehold improvements	7,543	101
Computers equipment & purchased software	373	146
Furniture & fixtures	66	8
Total property & equipment, gross	16,850	3,289
Less: Accumulated depreciation	1,588	121
Property & equipment, net	15,262	3,168
Other investments	500	...
Restricted cash	451	84
Other prepaid & non-current assets	319	...
Other non-current assets	1,270	84
Total assets	271,067	36,683
Accounts payable	1,963	1,713
Accrued liabilities	3,850	603
Accrued compensation	2,592	1,017
Current portion of deferred rent liability	538	...
Other current liabilities	163	148
Deferred rent & other current liabilities	701	148
Deferred rent	7,045	18
Other long-term liabilities	397	510
Total liabilities	16,548	4,009
Convertible preferred stock	348,673	48,308
Common stock	344	170
Additional paid-in capital	9,387	1,056
Accumulated other comprehensive income (loss)	(373)	...
Retained earnings (accumulated deficit)	(103,512)	(16,860)
Total stockholders' equity (deficit)	(94,154)	(15,634)

##### Recent Dividends:

##### 1. Denali Therapeutics Inc common.

No dividends paid.

##### Annual Dividends:

##### 1. Denali Therapeutics Inc common.

No dividends paid.

#### DIGI INTERNATIONAL INC

Acquisition Completed On Jan. 22, 2018, Co. acquired Accelerated Concepts, Inc., a provider of secure, enterprise-grade, cellular (LTE) networking equipment for primary and backup applications, for upfront cash of approximately \$17,000,000 with a potential for future earn-out consideration based on top line performance.

#### EHEALTH INC

Acquisition Completed On Jan. 22, 2018, Co. acquired all the outstanding membership interests of Wealth, Health and Life Advisors, LLC (d/b/a GoMedigap) ("GoMedigap") from WHL Advisors, Inc. ("WHL"), Qavah Ventures, LLC (together with WHL, the "Members"), Richard Cantu and Kevin Walbrick, and Kevin Walbrick as the exclusive member representative thereunder, for (i) at the Closing of the Acquisition, the Members received consideration consisting of \$15,000,000 in cash, less purchase price adjustments of \$171,250, and an aggregate of approximately 294,637 shares of Co. common stock, par value \$0.001 per share ("Co. Common Stock"), subject to escrow adjustments, and (ii) if, as and when payable under the Purchase Agreement, the Members would be entitled to receive earnout payments (the "Earnout Consideration") with an aggregate value equal to approximately \$30,000,000, consisting of approximately \$20,000,000 in cash and an aggregate of approximately 589,275 shares of Co. Common Stock. The Earnout Consideration would become payable, subject to the terms and conditions of the Purchase Agreement, upon the final determination of the achievement of certain milestones in 2018 and 2019.

#### EHEALTH INC

Acquisition Development on Jan. 16, 2018, Co. announced that it had entered into a definitive agreement to acquire Health, Wealth and Life Advisors, LLC, more commonly known as GoMedigap, a technology-enabled provider of Medicare Supplement enrollment services, for \$20,000,000 in cash and eHealth common stock, subject to purchase price and escrow adjustments.

In addition, GoMedigap membership interest holders have the potential to earn up to an additional \$30,000,000 of cash and eHealth common stock subject to the attainment of certain milestones in calendar years 2018 and 2019. The agreement to acquire GoMedigap is subject to customary closing conditions.

#### ENTEGRIS INC

**Acquisition Completed** On Jan. 22, 2018, Co. acquired Particle Sizing Systems, LLC, a company focused on particle sizing instrumentation for liquid applications in both semiconductor and life science industries, for approximately \$37,000,000 in cash, subject to customary working capital adjustments.

#### ENTELLUS MEDICAL INC

**Special Meeting of Stockholders** On Jan. 24, 2018, Co. scheduled its Special Meeting of Stockholders on Feb. 26, 2018, at 9:00 a.m., local time, at Fox Rothschild LLP, 222 South Ninth Street, Suite 2000, Minneapolis, MN 55402.

#### F5 NETWORKS, INC.

**Annual Meeting Development** On Jan. 26, 2018, Co. scheduled its annual Meeting of Shareholders for Mar. 15, 2018 at 11:00 a.m. Pacific Time at F5 Networks, Inc., 351 Elliott Avenue West, Seattle, WA 98119.

#### FIVE PRIME THERAPEUTICS, INC

**Offering** On Jan. 23, 2018, Co. announced today the pricing of an underwritten public offering of 5,128,205 shares of its common stock at a price to the public of \$19.50 per share. The size of the offering was upsized from \$75,000,000 to \$100,000,000. Co. estimates that the net proceeds from the sale of the shares will be approximately \$93,500,000, after deducting underwriting discounts and commissions and estimated offering expenses payable by Co. In addition, Co. has granted the underwriters in the offering a 30-day option to purchase up to 769,230 additional shares of common stock at the public offering price. The offering is expected to close on Jan. 29, 2018, subject to customary closing conditions.

#### FUTURE FINTECH GROUP INC

**Acquisition Development** On Jan. 23, 2018, Co.'s wholly-owned subsidiary, DigiPay FinTech Limited ("DigiPay"), and Peng Youwang ("Peng"), a Chinese citizen, entered into a DCON Digital Assets Transfer Agreement (the "Agreement"). Under the terms of the Agreement, Peng shall transfer to DigiPay a 60% ownership interest in certain digital assets of DCON, a blockchain platform for cryptocurrency conversion, payment and other services ("DCON"), including but not limited to its business plan and white papers, business models, software, codes, architectures, codes, software, applications, technologies, patents, copyrights, trade secrets, customer lists, business points, trading platforms, digital rights, authentication systems, agreements and contracts, intellectual property, token and the DCON communities established on Nova Realm City (the "Transfer Assets") for an aggregate purchase price of \$9,600,000 (the "Purchase Price"). Co. will pay the Purchase Price by issuing to Peng 1,200,000 shares of Co.'s common stock, par value \$0.001 per share (the "Common Stock"), equaling a per share sale price of \$8.00 (the "Share Payment"). Half of the shares of Common Stock subject to the Share Payment shall be issued within 30 days of the date of the Agreement, and the remaining Shares Payment shares shall be issued within 90 days of the date of the Agreement. The shares of Common Stock to be issued by Co. pursuant to the Share Payment under the Agreement shall be sold and issued pursuant to the exemption from registration provided by Regulation S promulgated under the Securities Act of 1933, as amended. The Agreement also contains customary representations and warranties regarding the Transfer Assets and the ownership thereof, and covenants regarding the parties' cooperation. DigiPay and Peng further agreed to establish a Japanese operating company for the Transfer Assets, of which DigiPay will hold a 60% ownership interest and Peng's designee will hold a 40% ownership interest.

#### FUTURE FINTECH GROUP INC

**Special Meeting of Shareholders** On Jan. 24, 2018, Co. announced that a Special Meeting of Shareholders will be held on Mar. 13, 2018, at 10:00 A.M., local time at Co.'s principal executive offices, located at 23F, China Development Bank Tower, No.2, Gaixin 1st Road, XiSan, Shaanxi, China.

#### GOLDEN ENTERTAINMENT INC

**Secondary Offering** On Jan. 16, 2018, Co. announced today the pricing of its underwritten secondary public offering of 6,500,000 shares of common stock to be sold by certain of its shareholders at a public offering price of \$28.00 per share. In addition, Co. has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares directly from Co. at the public offering price, less the underwriting discounts and commissions.

#### GOLFSMITH INTERNATIONAL HOLDINGS INC

**Bankruptcy Proceedings** On Jan. 23, 2018, the U.S. Bankruptcy Court scheduled a Jan. 23, 2018 hearing to consider Co.'s settlement and the committee's dismissal motion. This is the same date by which interested parties must file objections to Co.'s motion for an exclusivity extension.

#### GOLFSMITH INTERNATIONAL HOLDINGS INC

**Bankruptcy Proceedings** On Jan. 25, 2018, the U.S. Bankruptcy Court issued an order approving Co.'s and its official committee of unsecured creditors' joint motion for entry of an order authorizing dismissal of the Debtors' cases. The dismissal order states, "The Debtors are authorized to make distributions detailed in the motion in accordance with the Wind Down Budget attached as Exhibit 2. According to the budget the estate wind-down expenses is forecast as \$846,000. The final pay-out will be 50% of the reconciled claim amount of up to \$1,250,000 in aggregate." As previously reported, "Given the closing of the Sales and the lack of any remaining assets to monetize, the Debtors, the Creditors' Committee, and the Second Lien Parties have decided that implementing the Global Settlement through dismissal of these chapter 11 cases and the 503(b)(9) Procedures Motion is the most effective way to conclude these cases. Importantly, the Movants do not believe that it is possible to propose a confirmable chapter 11 plan. However, even if it was possible, confirmation will take too long, be too expensive, and substantially increase administrative costs. Moreover, given that substantially all of the Debtors' assets have already been liquidated, conversion of these cases to cases under chapter 7 will only add another layer of administrative expenses without any attendant benefit to the Debtors' creditors. In sum, the Global Settlement is the Debtors' best exit option from chapter 11." This specialty retailer of golf and tennis equipment, apparel, footwear and related accessories, filed for Chapter 11 protection on Sept. 14, 2016, listing \$125,000,000 in pre-petition assets. Also on Jan. 25, 2018, the U.S. Bankruptcy Court issued an order approving Co.'s and its official committee of unsecured creditor's joint motion for entry of an order establishing procedures for the allowance, settlement and payment of 503(b)(9) claims. As previously reported, "As part of the Global Settlement, the Debtors, the Creditors' Committee, and the Second Lien Parties decided and agreed that, under the facts of these cases where confirming a chapter 11 plan is not a reasonable possibility, resolving 503(b)(9) Claims through the 503(b)(9) Procedures was far more cost-effective and efficient than the traditional claims reconciliation process of setting a bar date and filing and prosecuting omnibus claims objections. Importantly, in the absence of the Global Settlement, which includes the 503(b)(9) Procedures contemplated herein and the creation of a \$1,250,000 reserve for the benefit of the holders of 503(b)(9) Claims, it is unclear whether the holders of 503(b)(9) claims would receive any recovery. Since the closing of the Sales, the Debtors, the Creditors' Committee, the Second Lien Trustee, Fairfax Financial Holdings Limited, and certain investment funds managed by CI Investments, the 'Second Lien Parties' have been in negotiations regarding the use of the Second Lien Collateral to pay, among other things, the 503(b)(9) Claims. In particular, the Creditors' Committee has asserted that the Debtors may surcharge the Second Lien Collateral to pay such claims while the Second Lien Parties have asserted that such a surcharge is improper."

#### GOLFSMITH INTERNATIONAL HOLDINGS INC

**Bankruptcy Proceedings** On Jan. 26, 2018, the U.S. Bankruptcy Court issued an order approving Co.'s fourth motion for entry of an order extending the exclusive periods during which only the Debtors may file a Chapter 11 plan and solicit acceptances thereof through and including Mar. 14, 2018 and May 14, 2018, respectively. As previously reported, "The Debtors are seeking the extension of the Exclusive Periods to permit them, together with their creditor constituencies, to pursue the consensual exit strategy contemplated by the Wind Down Motions and pay valid, undisputed administrative expenses without the interruption or distraction that could otherwise result from the filing of a proposed chapter 11 plan. Termination of the Exclusive Periods at this time would be a serious detriment to the Debtors' estates and to interested parties that have invested significant time and resources in these chapter 11 cases. Such termination would adversely impact the Debtors' efforts to preserve and maximize the value of these estates and the progress of the chapter 11 cases, dis-incentivize creditors from negotiating with the Debtors, and reduce the Debtors' prospects from successfully exiting these chapter 11 cases. In addition, the filing of any plan by a party other than the Debtors could potentially complicate and significantly increase the cost of administering these chapter 11 cases."

#### HARVARD BIOSCIENCE INC.

**Acquisition Development** On Jan. 22, 2018, Co. entered into a definitive merger agreement to acquire 100% of the outstanding stock of Data Sciences International, Inc. ("DSI") for

approximately \$70,000,000 (subject to adjustment for net working capital and other customary adjustments).

#### HARVARD BIOSCIENCE INC.

**Interest Sale Completed** On Jan. 22, 2018, Co. sold its wholly-owned subsidiary Denville Scientific, Inc. to Thomas Scientific, LLC for approximately \$20,000,000, which includes a \$3,000,000 earn-out provision.

#### HAYNES INTERNATIONAL, INC.

**Annual Meeting Development** On Jan. 26, 2018, Co. scheduled its annual Meeting of Shareholders for Wednesday, Feb. 28, 2018, at 10:00 a.m. (EST) at the Sheraton Indianapolis Hotel at Keystone Crossing, Indianapolis, IN 46240.

#### HOLOGIC INC

**Annual Meeting Development** On Jan. 26, 2018, Co. scheduled its annual Meeting of Shareholders for Mar. 14, 2018 at 8:00 a.m., Eastern Time, at Co.'s office, 250 Campus Drive, Marlborough, MA 01752.

#### HOLOGIC INC

**Co. Repurchasing Certain Securities** On Jan. 29, 2018, Co. announced that holders of the 2.00% Convertible Senior Notes due 2042 (CUSIP No. 436440 AC5) issued Mar. 5, 2012 have the right to surrender their notes for repurchase by Co. This right is pursuant to the put option under the base indenture governing the notes dated Dec. 10, 2007, as supplemented by the third supplemental indenture dated Mar. 5, 2012 (collectively, the "indenture"). The put option entitles each holder of the notes to require Co. to repurchase in cash all or part (in principal amounts equal to \$1,000 or multiples thereof) of the notes on Mar. 1, 2018 (the put option repurchase date) at a price equal to 100% of the accreted principal amount of the notes, plus accrued and unpaid interest, if any, upon the terms and subject to the conditions set forth in the indenture and the notes. Unless Co. defaults on the payment, interest on the notes surrendered for repurchase will cease to accrue on and after Mar. 1, 2018. As of the date of this notice, \$206,017,000 aggregate original principal amount of notes is outstanding. The opportunity to exercise the put option commences on Jan. 31, 2018 at 9 a.m. Eastern Time (ET), and expires at 5 p.m. ET on Feb. 28, 2018 (the expiration date), which is the business day immediately preceding the put option repurchase date. Holders may withdraw any notes previously surrendered for repurchase at any time prior to 5 p.m. ET on the expiration date. To exercise the put option, or withdraw notes previously surrendered, a holder must follow the procedures set forth in the put right notice that is being delivered to all registered holders of the notes.

#### IMPAX LABORATORIES INC

**Interest Sale Completed** On Jan. 30, 2018, Co. sold 100% interest of its wholly-subsiidiary, CorePharma, LLC, including its facilities and equipment in Middlesex, NJ, to a group of industry investors. Terms of the transaction were not disclosed.

#### INTERNATIONAL SPEEDWAY CORP

##### Annual Report

**Consolidated Income Statement, Years Ended Nov. 30 (\$000):**

	2017	2016 (revised)	2015 (revised)
Revenues - admissions, net . . . . .	121,505	123,521	130,154
Revenues - motorsports & other event related . . . . .	491,664	477,197	451,838
Revenues - food, beverage & merchandise . . . . .	41,293	41,968	47,282
Other revenues . . . . .	16,971	18,330	16,096
Total revenues . . . . .	671,433	661,016	645,370
NASCAR event management fees . . . . .	178,403	171,836	167,841
Motorsports & other event related . . . . .	134,136	133,322	131,109
Food, beverage & merchandise . . . . .	29,593	30,142	38,484
Other direct expenses . . . . .	1,581	483	1,397
General & administrative . . . . .	111,279	110,345	110,220
Depreciation & amortization . . . . .	109,733	102,156	94,727
Losses on retirements of long-lived assets . . . . .	10,552	2,905	16,015
Total expenses . . . . .	575,277	551,189	559,793
Operating income . . . . .	96,156	109,827	85,577
Interest income . . . . .	1,220	270	157
Interest expense . . . . .	11,633	13,837	9,582

Other income	344	12,896	730
Equity in net (loss) income from equity investments	19,111	14,913	14,060
Income (loss) before income taxes	105,198	124,069	90,942
Current federal income tax expense	6,888	(27,061)	46,095
Current state income tax expense	1,440	1,856	3,891
Deferred federal income tax expense (benefit)	(10,912)	70,186	(15,164)
Deferred state income tax expense	(3,041)	2,750	(514)
Income taxes	(5,625)	47,731	34,308
<b>Net income (loss)</b>	<b>110,823</b>	<b>76,338</b>	<b>56,634</b>
Weighted average shares			
outstanding-basic	44,649	45,981	46,621
Weighted average shares			
outstanding-diluted	44,660	45,996	46,636
Year end shares			
outstanding	43,821	44,690	46,290
Net income (loss) per share-basic	\$2.48	\$1.66	\$1.21
Net income (loss) per share-diluted	\$2.48	\$1.66	\$1.21
Dividends per share	\$0.43	\$0.41	\$0.26
Number of full time employees	820	792	807
Number of class A common stockholders	1,847	1,934	2,017
Number of class B common stockholders	290	344	319

Reclassified to conform with 2017 presentation; As is; Approximately

#### Consolidated Balance Sheet, Years Ended Nov. 30 (\$000):

	2017	2016
		(revised)
Cash & cash equivalents	256,702	263,727
Receivables, gross	38,269	36,445
Less: allowance for doubtful accounts	1,000	1,000
Receivables, net	37,269	35,445
Income taxes receivable	21,867	189
Prepaid expenses & other current assets	9,749	13,759
Total current assets	325,587	313,120
Land & leasehold improvements	244,539	244,337
Buildings, grandstands & motorsports entertainment facilities	1,845,958	1,831,804
Furniture & equipment	266,622	258,510
Construction in progress	153,034	55,011
Property & equipment, gross	2,510,153	2,389,662
Less accumulated depreciation	1,030,410	934,156
Property & equipment, net	1,479,743	1,455,506
Equity investments	86,200	92,392
Intangible assets, net	178,637	178,629
Goodwill	118,400	118,791
Other assets	19,625	14,222
Total assets	2,208,192	2,172,660
Current portion of long-term debt	3,854	3,404
Accounts payable	23,936	29,770
Deferred income	38,521	39,416
Other current liabilities	19,249	22,728
Total current liabilities	85,560	95,318
Unsecured senior notes	165,000	165,000
Term loan	46,975	47,878
TIF bond debt service funding commitment	49,368	52,145
Less: current portion	4,091	3,738
Less: unamortized discounts & debt issuance costs	(1,640)	(1,869)

Deferred income taxes	396,046	409,585
Long-term deferred income	8,251	5,988
Other long-term liabilities	2,801	1,993
Class A common stock	241	249
Class B common stock	197	197
Additional paid-in capital	430,114	437,292
Retained earnings	1,031,361	965,281
Accumulated other comprehensive income (loss)	(1,991)	(2,659)
Total shareholders' equity	1,459,922	1,400,360

#### Recent Dividends:

##### 1. International Speedway Corp class A common.

ExDate	Amt	Declared	Record	Payable
05/27/2015	0.26	04/08/2015	05/29/2015	06/30/2015
05/26/2016	0.41	04/13/2016	05/31/2016	06/30/2016
	0.43	04/13/2017	05/31/2017	06/30/2017

##### 2. International Speedway Corp class B common.

No dividends paid.

#### Annual Dividends:

##### 1. International Speedway Corp class A common.

2015	0.26	2016	0.41	2017	0.43
------	------	------	------	------	------

##### 2. International Speedway Corp class B common.

No dividends paid.

#### IOVANCE BIOTHERAPEUTICS INC

**Offering** On Jan. 24, 2018, Co. announced the pricing of an underwritten public offering of 13,043,479 shares of its common stock at a public offering price of \$11.50 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Co., are expected to be \$150,000,000. In addition, Co. has granted the underwriters a 30-day option to purchase up to 1,956,521 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about Jan. 29, 2018, subject to customary closing conditions.

#### JUNO THERAPEUTICS INC

**Merger Development** On Jan. 21, 2018, Celgene Corp. ("Celgene") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Co., and Blue Magpie Corp. a wholly-owned subsidiary of Celgene ("Purchaser"), pursuant to which, among other things, subject to the terms and conditions of the Merger Agreement, Purchaser will commence a tender offer (the "Offer") for all of the outstanding shares of common stock of Co., par value \$0.0001 per share ("Co.'s Shares"), at a purchase price of \$87.00 per Co. Share, net to the seller in cash, subject to reduction for any applicable withholding taxes (the "Offer Price").

Following the completion of the Offer and subject to the terms and conditions of the Merger Agreement, Purchaser will merge with and into Co., with Co. surviving as a wholly-owned subsidiary of Celgene, pursuant to the procedures provided for under Section 251(h) of the Delaware General Corporation Law without any stockholder approvals (the "Merger"). At the effective time of the Merger (the "Effective Time"), each outstanding Co.'s Share, other than any shares owned by (i) Co. (or held in its treasury), (ii) Celgene, Purchaser, or any other direct or indirect wholly owned subsidiary of Celgene, or (iii) any stockholders who are entitled to and who properly exercise and perfect appraisal rights under Delaware law (and have neither withdrawn nor lost their rights), will be automatically converted into the right to receive an amount in cash equal to the Offer Price, without interest. The Celgene Board of Directors has, by unanimous vote, approved the Merger Agreement, the Merger and the other transactions contemplated by the Merger Agreement. Pursuant to the terms of the Merger Agreement, each outstanding unvested Co. stock option ("Option"), each outstanding award of Co. time-based restricted stock units ("RSUs"), and each outstanding award of Co. time-based restricted stock awards ("RSAs"), (i) if granted twelve (12) months or more prior to the Effective Time, will become vested pursuant to their respective terms or, if greater, with respect to 25% of the total number of Juno Shares subject to such award, (ii) if granted following the date of the Merger Agreement but prior to the Effective Time, will become vested pursuant to their respective terms or, if greater, with respect to 25% of the total number of Co.'s Shares subject to such award (the "Pre-Closing Non-Performance

Awards"), or (iii) if granted less than twelve (12) months prior to the Effective Time (other than the Pre-Closing Non-Performance Awards), will become vested pursuant to their respective terms or, if greater, with respect to that number of Co.'s Shares subject thereto, such that, following such vesting, the award will be unvested with respect to that number of Co.'s Shares which would have become vested and resulted in the award being 100% vested had the holder of the award remained continuously employed for an additional twenty-four months following the Effective Time; provided, that, with respect to any awards referred to in subsections (i) and (iii) above, if, as of the 24-month anniversary of the Effective Time, any portion of such awards remains unvested, such unvested portion will become immediately vested on such 24-month anniversary date, provided that the employee has remained employed through such 24-month anniversary date. All such awards that become vested or that are otherwise vested as of immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement) will be cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of Co.'s Shares subject to such vested award and (ii) the Offer Price (reduced by the applicable exercise price in the case of Juno options). The Merger Agreement provides that Options, RSUs and RSAs that are outstanding immediately prior to the Offer Acceptance Time but unvested after giving effect to the vesting acceleration described above will be assumed by Celgene and will be subject to the same terms and conditions (except with respect to the vesting schedule), as applied to each such equity-based award immediately prior to the Effective Time, provided that the number of shares subject to such equity-based awards (and the exercise price in the case of the Options) will be adjusted based on the "Exchange Ratio." The "Exchange Ratio" means an amount equal to the quotient obtained by dividing (i) the Offer Price, by (ii) the volume weighted average price per share of Celgene's common stock on the Nasdaq Stock Market for the fifteen consecutive trading days ending on the complete trading day immediately prior to the Offer Acceptance Time. The Merger Agreement also provides that all Juno performance-based restricted stock units ("PSUs") and all Co. performance-based restricted stock awards ("PSAs") will vest as to 50% of the total number of PSUs or PSAs (as applicable) subject to such awards, and such vested portion will be cancelled and converted into the right to receive an amount in cash equal to the product of (i) such 50% vested portion of the award, and (ii) the Offer Price. The remaining 50% of the PSUs and PSAs will be assumed by Celgene and will be subject to the same terms and conditions as were applicable to such awards immediately prior to the Offer Acceptance Time, provided that the number of shares subject to such equity-based awards (and the exercise price in the case of the Options) will be adjusted based on the Exchange Ratio, except that (i) 60% of such remaining award will vest on the one-year anniversary of the Effective Time and (ii) 40% of such remaining award will vest on the earlier of (A) the second anniversary of the Effective Time and (B) the first approval by the FDA of JCAR017.

#### KEURIG GREEN MOUNTAIN INC

**Merger Development** On Jan. 29, 2018, Co. and Dr Pepper Snapple Group, Inc. ("Dr Pepper Snapple") announced that the companies have entered into a definitive merger agreement to create Keurig Dr Pepper ("KDP"), a new beverage company of scale with a portfolio of iconic consumer brands and unrivaled distribution capability to reach virtually every point-of-sale in North America. Under the terms of the agreement, which has been unanimously approved by the Dr Pepper Snapple Board of Directors, Dr Pepper Snapple shareholders will receive \$103.75 per share in a special cash dividend and retain 13% of the combined company.

#### KEY TECHNOLOGY INC

**Merger Development** On Jan. 25, 2018, Co. entered into an Agreement and Plan of Merger (the "Merger Agreement") with Duravant LLC ("Duravant") and Cascade Merger Sub, Inc., a wholly owned subsidiary of Duravant ("Merger Sub"). Pursuant to the terms of the Merger Agreement, Merger Sub will commence a tender offer to acquire all of the outstanding shares of the common stock, no par value, of Co., at a price per share of \$26.75, net to the seller in cash, without interest and subject to any withholding of taxes.

#### CLA-TENCOR CORP.

**Earnings, 6 mos. to Dec 31 (Consol. - \$000):**

	2017	2016
Total Revenues	1,945,403	1,627,558
Cost & expenses	1,217,519	1,044,408
Operating income	683,459	529,065
Interest expense	57,948	61,356
Other income (expense), net	13,523	7,271
Net before taxes	683,459	529,065
Income taxes	536,842	112,713

<b>Net income</b> .....	146,617	416,352
Earnings common share		
Primary .....	\$0.94	\$2.66
Fully Diluted .....	\$0.93	\$2.65
Common Shares:		
Full Diluted .....	157,688	157,071
Year-end .....	156,620	156,729

**LAM RESEARCH CORP**

Earnings, 6 mos. to (Consol. - \$000):

	12/24/17	12/25/16
Total Revenues .....	5,058,955	3,514,718
Cost & expenses .....	3,628,362	2,758,943
Operating income .....	1,430,593	755,775
Interest income .....	40,787	23,708
Other income (expense), net .....	(415)	(36,045)
Foreign currency .....	(1,804)	2,230
Net before taxes .....	1,421,939	677,598
Income taxes .....	841,204	80,972
<b>Net income</b> .....	580,735	596,626
Earnings common share		
Primary .....	\$3.59	\$3.69
Fully Diluted .....	\$3.16	\$3.28
Common Shares:		
Full Diluted .....	183,958	181,780
Year-end .....	159,451	162,357

**LIFEAPPS BRANDS INC**

**New Accountant** On Jan. 23, 2018, Pritchett, Siler & Hardy, P.C. resigned as Co.'s independent public accounting firm, subsequently, Co. engaged Haynie & Company as its new independent public accounting firm.

**LIQUIDITY SERVICES INC**

**Annual Meeting Development** On Jan. 22, 2018, Co. scheduled its annual Meeting of Shareholders for Thursday, Feb. 22, 2018, at 3:00 p.m., Eastern Time, at Co.'s office located at 6931 Arlington Road, Suite 200, Bethesda, MD 20814.

**MENLO THERAPEUTICS INC**

**Offering** On Jan. 23, 2017, Co. announced a public offering pursuant to Common Stock, par value \$0.0001 per value. Co. proposed to offer 7,475,000 at a proposed maximum offering price per share of \$17.00 which amounted to a proposed maximum aggregate offering price of \$127,075,000. The amount of registration fee is \$15,820.84.

**METASTAT, INC**

Earnings, 9 mos. to Nov 30(Consol. - \$):

	2017	2016
Total Revenues .....	23,300	.....
Cost & expenses .....	2,695,475	2,517,230
Operating income .....	(553)	(4,672)
Other income (expense), net .....	552,404	12,746
<b>Net income</b> .....	(2,209,464)	(3,486,030)
Balance for common .....	(2,313,347)	(6,731,079)
Earnings common share		
Primary .....	\$(0.44)	\$(2.81)
Fully Diluted .....	\$(0.44)	\$(2.81)
Common Shares:		
Full Diluted .....	5,259,190	2,397,028
Year-end .....	5,677,383	4,707,942

**NETFLIX INC****Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2017	2016	2015
		(revised)	(revised)
Revenues .....	11,692,713	8,830,669	6,779,511
Cost of revenues .....	7,659,666	6,029,901	4,591,476
Marketing expenses ..	1,278,022	991,078	824,092
Technology & development expenses .....	1,052,778	852,098	650,788
General & administrative expenses .....	863,568	577,799	407,329
Operating income (loss) .....	838,679	379,793	305,826
Interest expense .....	238,204	150,114	132,716
Interest & other income (expense) ....	(115,154)	30,828	(31,225)
Income before income taxes - United States .....	144,100	188,078	95,644
Income (loss)			

before income taxes							Other non-current assets .....	652,309	341,423
- foreign .....	341,221	72,429	46,241				Total assets .....	19,012,742	13,586,610
Income (loss)							Current content		
before income taxes ..	485,321	260,507	141,885				liabilities .....	4,173,041	3,632,711
Current tax							Accounts payable .....	359,555	312,842
provision (benefit)							Accrued expenses .....	315,094	197,632
- federal .....	54,245	54,315	52,557				Deferred revenue .....	618,622	443,472
Current tax							Total current liabilities .....	5,466,312	4,586,657
provision (benefit)							Non-current content		
- state .....	(7,601)	5,790	(1,576)				liabilities .....	3,329,796	2,894,654
Current tax							Long-term debt .....	6,499,432	3,364,311
provision (benefit)							Other non-current		
- foreign .....	88,436	60,571	26,918				liabilities .....	135,246	61,188
Total current tax							Total liabilities .....	15,430,786	10,906,810
provision (benefit) ...	135,080	120,676	77,899				Common stock .....	1,871,396	1,599,762
Deferred tax							Foreign currency .....	(20,557)	(47,966)
provision (benefit)							Change in unrealized		
- federal .....	(153,963)	(24,383)	(37,669)				gains on available for		
Deferred tax							sale securities .....	...	(599)
provision (benefit)							Accumulated other		
- state .....	(52,695)	(14,080)	(17,635)				comprehensive income		
Deferred tax							(loss) .....	(20,557)	(48,565)
provision (benefit)							Retained earnings		
- foreign .....	(2,030)	(8,384)	(3,351)				(accumulated deficit) .....	1,731,117	1,128,603
Total deferred tax							Total stockholders'		
provision (benefit) ...	(208,688)	(46,847)	(58,655)				equity (deficiency) .....	3,581,956	2,679,800
Provision for									
(benefit from)									
income taxes .....	(73,608)	73,829	19,244						
<b>Net income (loss)</b> ....	558,929	186,678	122,641						

**Recent Dividends:****1. Netflix Inc common.**

ExDate	Amt	Declared	Record	Payable
	0.00			07/14/2015
After 600% split:				
ExDate	Amt	Declared	Record	Payable
	0.00			07/14/2015

**Annual Dividends:****1. Netflix Inc common.**

2015 .....	0.00
After 600% split:	
2015 .....	0.00

**NEWMARK GROUP INC****Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

	2016	2015
Commissions .....	849,419	806,931
Gain from mortgage banking activities, net .....	193,387	115,304
Management services, servicing fees & other .....	307,177	278,012
Total revenues .....	1,349,983	1,200,247
Compensation & employee benefits .....	849,975	816,268
Allocations of net income & grant of exchangeability to limited partnership units .....	72,318	142,195
Total compensation & employee benefits .....	922,293	958,463
Operating, administrative & other .....	185,344	162,316
Fees to related parties .....	18,010	18,471
Depreciation & amortization .....	72,197	71,774
Total operating expenses .....	1,197,844	1,211,024
Other income (loss) .....	15,279	(460)
Total other income (loss), net .....	15,279	(460)
Income (loss) from operations .....	167,418	(11,237)
Interest income, net .....	3,787	1,867
Income (loss) before income taxes & noncontrolling interests .....	171,205	(9,370)
Current federal income taxes .....	4,253	3,648
Current state income taxes .....	599	975
Current foreign income		

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):**

	2017	2016
		(revised)
Cash & cash equivalents .....	2,822,795	1,467,576
Short-term investments .....	...	266,206
Current content assets, net .....	4,310,934	3,726,307
Other current assets .....	536,245	260,202
Total current assets .....	7,669,974	5,720,291
Non-current content assets, net .....	10,371,055	7,274,501
Information technology assets .....	223,850	185,345
Furniture & fixtures .....	49,217	32,185
Building .....	40,681	40,681
Leasehold improvements .....	229,848	107,945
DVD operations equipment .....	59,316	70,152
Corporate aircraft .....	30,039	...
Capital work-in-progress .....	8,267	108,296
Property & equipment, gross .....	641,218	544,604
Less: accumulated depreciation .....	321,814	294,209
Property & equipment, net .....	319,404	250,395

□ As is; □ Approximately; □ As of January 27, 2016; □ As reported by the Company; □ As of January 25, 2018; □ As of January 26, 2017

taxes	169	13
Current income taxes - UBT	113	1
Current income taxes	5,134	4,637
Deferred federal income taxes	(488)	(10,571)
Deferred state income taxes	(562)	(695)
Deferred income taxes - UBT	(91)	(15)
Deferred income taxes	(1,141)	(11,281)
Provision for income taxes	3,993	(6,644)
<b>Net income (loss)</b>	167,212	(2,726)
Net income (loss) attributable to noncontrolling interest	1,189	(77)
Net income (loss) to BGC Partners	168,401	(2,803)
Total number of employees	14,600	...

□ As is; □ Over

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

	2016	2015
Cash & cash equivalents	66,627	111,430
Restricted cash & cash equivalents	50,927	48,742
Loans held for sale	1,071,836	359,109
Accounts receivable, gross	162,540	176,476
Provision for doubtful accounts	11,371	17,866
Receivables, net	151,169	158,610
Receivable from related parties	108,817	125,842
Derivative assets	19,924	9,531
Prepaid expenses	10,728	10,560
Rent & other deposits	2,585	3,035
Other current assets	132	60
Other current assets	33,369	23,186
Total current assets	1,482,745	826,919
Goodwill	412,846	393,028
Mortgage servicing rights, net	339,816	263,913
Loans, forgivable loans & other receivables from employees & partners	184,159	91,732
Leasehold improvements & other fixed assets	63,194	36,959
Software, including software development costs	13,971	10,475
Computer & communications equipment	13,291	11,474
Total property & equipment, gross	90,456	58,908
Less accumulated depreciation & amortization	34,006	33,116
Fixed assets, net	56,450	25,792
Other intangible assets, net	30,312	27,104
Deferred tax assets	23,074	24,251
Cost method investments	2,896	2,596
Other assets	2,390	2,595
Other assets	28,360	29,442
Total assets	2,534,688	1,657,930
Accounts payable & accrued expenses	57,488	48,733
Payroll taxes payable	2,898	2,469
Contingent consideration	20,458	20,536
Outside broker payable	17,712	14,492
Derivative liability	9,670	3,231
Current portion of accounts payable, accrued expenses & other liabilities	108,226	89,461
Payable to related parties	889,162	147,488
Warehouse notes payable	257,969	359,633
Accrued compensation	155,017	129,437
Total current liabilities	1,410,374	726,019
Financial guarantee liability		413

Deferred rent	41,545	20,894
Credit enhancement deposit	25,000	25,000
Accrued compensation	23,953	19,089
Payroll taxes payable	28,569	20,950
Contingent consideration	18,255	38,096
Deferred tax liability	2,796	3,560
Other long-term liabilities	140,531	127,877
Total liabilities	1,550,905	853,896
BGC Partners' net investment in Newmark	981,776	800,193
Non-controlling interests	2,007	3,841
Total invested equity	983,783	804,034

Recent Dividends:

1. Newmark Group Inc class A common.

No dividends paid.

2. Newmark Group Inc class B common.

No dividends paid.

Annual Dividends:

1. Newmark Group Inc class A common.

No dividends paid.

2. Newmark Group Inc class B common.

No dividends paid.

NOBILITY HOMES, INC.

Annual Report

Consolidated Income Statement, Years Ended (\$):

	11/04/17	11/05/16	10/31/15 (revised)
Net sales	37,543,071	34,053,290	27,836,804
Cost of goods sold	28,881,992	26,117,155	21,701,429
Gross profit	8,661,079	7,936,135	6,135,375
Selling, general & administrative expenses	4,305,205	3,782,336	3,193,923
Operating income (loss)	4,355,874	4,153,799	2,941,452
Interest income	149,613	112,802	59,985
Undistributed earnings in joint venture - Majestic			
21	103,533	123,772	138,469
Proceeds received under escrow arrangement	504,548	788,566	...
Gain on sale of investment in retirement community, net	...	3,990,000	...
Gains (losses) from investments in retirement community limited partnerships	...	...	(146,403)
Miscellaneous income (loss) before provision for income taxes	54,682	15,297	57,698
Income (loss) before provision for income taxes	5,168,250	9,184,236	3,051,201
Current tax expense (benefit) - federal	1,689,446	769,463	5,629
Current tax expense (benefit) - state	287,699	...	...
Total current tax expense (benefit)	1,977,145	769,463	5,629
Deferred tax expense (benefit)	(118,878)	2,449,579	1,105,489
Valuation allowance	...	...	(975,312)
Income tax expense (benefit)	1,858,267	3,219,042	135,806
<b>Net income (loss)</b>	3,309,983	5,965,194	2,915,395
Weighted average shares outstanding - basic	4,002,436	4,021,019	4,052,865
Weighted average shares outstanding - diluted	4,003,768	4,022,083	4,053,362
Year end shares outstanding	3,997,569	4,003,607	4,031,569
Net earnings (loss) per share - basic	\$0.83	\$1.48	\$0.72

Net earnings (loss) per share - diluted	\$0.83	\$1.48	\$0.72
Number of full time employees	147	140	129
Number of common stockholders	113	125	132

□ As of January 5, 2018; □ As of January 6, 2017; □ As of January 4, 2016; □ Approximately; □ As of January 26, 2018; □ As of January 27, 2017; □ As of January 28, 2016

Consolidated Balance Sheet, Years Ended (\$):

	11/04/17	11/05/16
Cash & cash equivalents	27,910,504	24,562,638
Accounts receivable - trade	2,934,300	2,641,763
Notes receivable	500,000	500,000
Mortgage notes receivable, current	13,495	9,717
Raw materials	896,954	717,525
Work-in-process	110,847	120,693
Finished homes	6,369,495	6,025,268
Model home furniture	128,385	105,595
Pre-owned homes, current	1,141,863	1,295,694
Property held for sale	...	213,437
Prepaid expenses & other current assets	820,224	638,939
Deferred income taxes	609,629	556,773
Total current assets	42,062,783	37,869,067
Land	2,870,463	2,870,463
Land improvements	743,956	689,043
Buildings & improvements	2,194,435	2,019,429
Machinery & equipment	786,708	749,360
Furniture & fixtures	277,386	223,537
Property, plant & equipment, at cost	6,872,948	6,551,832
Less: accumulated depreciation	2,568,177	2,488,121
Property, plant & equipment, net	4,304,771	4,063,711
Pre-owned homes	815,358	1,733,610
Interest receivable	101,301	48,376
Note receivable, less current portion	1,134,086	2,030,000
Mortgage notes receivable, long term	240,297	174,270
Other investments	1,471,029	1,367,496
Property held for sale	599,455	386,018
Cash surrender value of life insurance	3,262,848	3,085,916
Other assets	156,287	156,287
Total assets	54,148,215	50,914,751
Accounts payable	849,782	835,279
Accrued compensation	624,989	682,815
Accrued warranty expense	125,000	125,000
Accrued property & sales taxes	359,957	299,710
Other accrued expenses	642,440	698,988
Income taxes payable	260,416	759,128
Customer deposits	2,796,827	1,706,795
Total current liabilities	5,659,411	5,107,715
Deferred income taxes	1,074,507	1,140,529
Total liabilities	6,733,918	6,248,244
Common stock	536,491	536,491
Additional paid in capital	10,669,231	10,663,348
Retained earnings (accumulated deficit)	46,167,528	43,458,271
Accumulated other comprehensive income	412,233	266,171
Less treasury stock at cost	10,371,186	10,257,774
Total stockholders' equity (deficit)	47,414,297	44,666,507

Recent Dividends:

1. Nobility Homes, Inc. common.

ExDate	Amt	Declared	Record	Payable
03/23/2017	0.15	03/17/2017	03/27/2017	04/17/2017

Annual Dividends:

1. Nobility Homes, Inc. common.



2017.....0.15

**NUANCE COMMUNICATIONS INC**

**Annual Meeting Development** On Jan. 26, 2018, Co. scheduled its annual Meeting of Shareholders for Feb. 28, 2018 at 10:00 a.m. local time, at Co.'s office located at 1198 East Arques Avenue, Sunnyvale, CA 94085.

**OBALON THERAPEUTICS INC**

**Secondary Offering** On Jan. 16, 2018, Co. announced the pricing of an underwritten public offering of 5,454,545 shares of its common stock at a public offering price of \$5.50 per share. The offering is expected to close on or about Jan. 23, 2018, subject to customary closing conditions. Co. has granted the underwriters a 30-day option to purchase up to 818,181 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares are being sold by Co.

**OCULAR THERAPEUTIX INC**

**Offering** On Jan. 24, 2018, Co. announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a public offering price of \$5.00 per share for gross proceeds of \$32,500,000. This offering was made pursuant to a shelf registration statement that was previously filed with and declared effective by the Securities and Exchange Commission (SEC). All of the shares in the offering are to be sold by Co. In addition, Co. has granted the underwriter of the offering a 30-day option to purchase up to an additional 975,000 shares in the public offering on the same terms and conditions.

**PARATEK PHARMACEUTICALS INC**

**Secondary Offering** On Jan. 17, 2018, Co. announced that it has sold 3,205,128 shares of its common stock in a registered underwritten public offering for total proceeds of approximately \$50,000,000. The offering is expected to close on Jan. 22, 2018, subject to customary closing conditions. All of the shares sold in the offering were sold by Co. In addition, Co. has granted the underwriter a 30-day option to purchase up to an additional 480,769 shares of its common stock.

**PATRICK INDUSTRIES INC**

**Co. Repurchasing Certain Securities** On Jan. 30, 2018, Co. announced that its Board of Directors has approved a new stock repurchase program that authorizes the repurchase of up to \$50,000,000 of Co.'s common stock over the next 24 months (the "2018 Repurchase Plan"). Share repurchases will be made from time to time through open market transactions at prevailing market prices, or in privately negotiated transactions or otherwise. Co.'s previous stock repurchase program, which was originally announced in Jan. 2016 (the "2016 Repurchase Plan") and authorized repurchases of up to \$50,000,000 over a 24-month period, expired in Jan. 2018. Co. repurchased in the aggregate 75,153 shares under the 2016 Repurchase Plan at an average price of \$31.25 per share for a total cost of approximately \$2,350,000.

**PCM, INC**

**Acquisition Completed** On Jan. 24, 2018, Co. acquired certain assets of Epoch Universal, Inc. Terms of the transaction were not disclosed.

**PETIQ INC**

**Acquisition Completed** On Jan. 17, 2018, Co.'s wholly-owned subsidiary, PetIQ Holdings, LLC ("Holdings"), through its wholly-owned subsidiary, PetIQ, LLC ("Buyer"), acquired all the outstanding membership units of Community Veterinary Clinics, LLC ("VIP"), an operator and provider of nationwide veterinary clinics and veterinarian services within major U.S. retailers, from VIP Petcare Holdings, Inc. ("VIP Holdings") for (i) \$100,000,000 in cash, subject to adjustment for net working capital, (ii) 4,200,000 membership units of Holdings (the "LLC Units") and 4,200,000 shares of Class B common stock, \$0.001 par value per share, of Co. (the "Class B Issuance") and together with the LLC Units, the "Equity Consideration") and (iii) promissory notes consisting of (A) a \$10,000,000 note payable 5 years and 6 months after the closing, which shall accrue interest quarterly in arrears at a rate of 6.75% per annum, (B) a \$10,000,000 note payable 5 years and 6 months after the closing if Co. and its consolidated subsidiaries have EBITDA of \$40,000,000 for the year ending Dec. 31, 2018, which, if payable, shall accrue interest quarterly in arrears at a rate of 6.75% per annum beginning on the first anniversary of the closing, and (C) a \$10,000,000 note payable 5 years and 6 months after the closing if Co. and its consolidated subsidiaries have EBITDA of \$50,000,000 for the year ending Dec. 31, 2019, which, if payable, shall accrue interest quarterly in arrears at a rate of 6.75% per annum beginning on the second anniversary of the closing; provided that such note shall also become payable if Co. and its consolidated subsidiaries have EBITDA of \$50,000,000 for the year ending Dec. 31, 2018. As the result, VIP became an indirect wholly-owned subsidiary of Co.

**PROGRESS SOFTWARE CORP.****Annual Report****Consolidated Income Statement, Years Ended Nov. 30**

(\$000):	2017	2016 (revised)	2015 (revised)
Software licenses revenue	124,406	134,863	130,250
Maintenance & services revenue	273,166	270,478	247,304
Total revenue	397,572	405,341	377,554
Cost of software licenses	5,752	5,456	5,979
Cost of maintenance & services	43,299	44,760	40,933
Amortization of acquired intangibles	20,108	15,496	16,830
Total costs of revenue	69,159	65,712	63,742
Gross profit (loss)	328,413	339,629	313,812
Sales & marketing expenses	96,345	121,501	124,867
Product development	76,988	88,587	86,924
General & administrative expenses	45,739	46,532	57,294
Impairment of goodwill & intangible assets	...	97,051	...
Amortization of acquired intangibles	13,039	12,735	12,745
Fees related to shareholder activist	2,020	...	...
Restructuring expenses	22,210	1,692	12,989
Acquisition-related expenses	1,458	1,240	4,239
Total operating expenses	257,799	369,338	299,058
Income (loss) from operations	70,614	(29,709)	14,754
Interest expense	4,631	4,178	3,788
Interest income & other income (expense)	921	839	1,446
Foreign currency gain (loss)	(1,317)	(2,232)	(58)
Total other income (expense), net	(5,027)	(5,571)	(2,400)
Income (loss) before income taxes - U.S.	77,442	78,477	62,813
Income (loss) before income taxes - Foreign	(11,855)	(113,757)	(50,459)
Income (loss) before income tax provision	65,587	(35,280)	12,354
Current income taxes - federal	23,739	12,934	18,418
Current income taxes - state	2,461	3,178	1,526
Current income taxes - foreign	1,496	3,027	3,056
Total current income taxes	27,696	19,139	23,000
Deferred income taxes - federal	1,548	6,203	2,199
Deferred income taxes - state	61	(1,963)	60
Deferred income taxes - foreign	(1,135)	(2,933)	(4,104)
Total deferred income taxes	474	1,307	(1,845)
Income tax provision (benefit)	28,170	20,446	21,155
<b>Net income (loss)</b>	<b>37,417</b>	<b>(55,726)</b>	<b>(8,801)</b>
Weighted average shares outstanding - basic	48,129	49,481	50,391
Weighted average			

shares outstanding - diluted	48,516	49,481	50,391
Year end shares outstanding	47,281	48,537	50,580
Net income (loss) per share - basic	\$0.78	\$(1.13)	\$(0.17)
Net income (loss) per share - diluted	\$0.77	\$(1.13)	\$(0.17)
Cash dividends declared per common share	\$0.52	\$0.13	...
Total number of employees	1,470	1,912	1,766
Number of common stockholders	164	182	181
Foreign currency translation adjustments	9,655	(3,843)	(10,849)
<p>□ Reclassified to conform with 2017 presentation; □ Reclassified to conform with 2016 presentation; □ As is; □ Approximately; □ As of December 31, 2017; □ As of December 31, 2016; □ As of December 31, 2015</p>			
<b>Consolidated Balance Sheet, Years Ended Nov. 30 (\$000):</b>			
	2017	2016	(revised)
Cash & cash equivalents	133,464	207,036	
Short-term investments	50,145	42,718	
Accounts receivable, gross	61,886	66,821	
Less: allowances	676	1,143	
Accounts receivable, net	61,210	65,678	
Other current assets	18,588	20,621	
Total current assets	263,407	336,053	
Computer equipment & software	50,588	47,978	
Land, buildings & leasehold improvements	50,229	53,291	
Furniture & fixtures	7,211	7,080	
Capitalized software development costs	2,955	2,955	
Property & equipment, gross	110,983	111,304	
Less: accumulated depreciation & amortization	68,722	61,199	
Property & equipment, net	42,261	50,105	
Intangible assets, net	94,894	80,827	
Goodwill	315,041	278,067	
Deferred tax assets	1,123	6,601	
Other assets	1,992	3,174	
Total assets	718,718	754,827	
Current portion of long-term debt	5,819	15,000	
Accounts payable	9,000	12,991	
Accrued compensation & related taxes	32,373	26,212	
Dividends payable to shareholders	6,619	6,067	
Income taxes payable	1,173	1,509	
Other accrued liabilities	20,496	12,999	
Short-term deferred revenue	132,538	128,960	
Total current liabilities	208,018	203,738	
Long-term debt	116,090	120,000	
Long-term deferred revenue	9,750	8,801	
Deferred tax liabilities	2,809	3,901	
Other noncurrent liabilities	5,967	11,758	
Common stock	473	485	
Additional paid-in capital	249,363	239,011	
Retained earnings (accumulated deficit)	145,247	195,694	
Foreign currency translation adjustment	(18,770)	(28,425)	
Unrealized gains (losses) on investments	(229)	(136)	
Accumulated other comprehensive income (loss)	(18,999)	(28,561)	

Total shareholders' equity (deficit).....	376,084	406,629
---	---------	---------

**Recent Dividends:****1. Progress Software Corp. common.**

ExDate	Amt	Declared	Record	Payable
11/29/2016	0.13	09/28/2016	12/01/2016	12/15/2016
02/27/2017	0.13	01/11/2017	03/01/2017	03/15/2017
05/30/2017	0.13	03/24/2017	06/01/2017	06/15/2017
08/30/2017	0.13	06/21/2017	09/01/2017	09/15/2017
11/30/2017	0.14	09/12/2017	12/01/2017	12/15/2017

**Annual Dividends:****1. Progress Software Corp. common.**

2016.....	0.13	2017.....	0.52
-----------	------	-----------	------

**PTC INC**

**Annual Meeting Development** On Jan. 24, 2018, Co. announced that its Annual Meeting of Stockholders will be held on Mar. 8, 2018, at 8:00 a.m., local Time at Co.'s office located at 140 Kendrick Street, Needham, MA 02494.

**QUADRANT 4 SYSTEM CORP**

**Bankruptcy Proceedings** On Jan. 23, 2018, BIP Lender filed with the U.S. Bankruptcy Court an objection to Quadrant 4 Systems' motion for authority to enter into modification agreement with TriZetto Corporation. The objection asserts, "The motion seeks relief under 11 USC section 363, yet it provides no opportunities for counter offers or higher and better bids. The Debtor recites an effort to try and sell the TriZetto license rights in connection with the QHIX Healthcare Platform and avers that these efforts were unsuccessful, yet the Debtor does not suggest why it will not subject the TriZetto offer to purchase these rights to a bidding process in which others might be allowed to compete against TriZetto. This is essentially the crux of the Motion, the Debtor believes that the estate is better off with cash now, presumably yielding no return for unsecured creditors, versus retaining its rights to litigation claims and payment later. It is hard to understand why the latter option is not being considered." BIP Lender also filed a separate objection to the Debtor's motion to extend exclusivity period, arguing, "The Debtor has not articulated a good faith basis to further extend the period. The Debtor is engaged in an effort to sell its final asset in a manner that contravenes the best interests of BIP as a potentially undersecured creditor." Also on Jan. 23, 2018, the U.S. Bankruptcy Court scheduled a Jan. 23, 2018 hearing to consider Co.'s extension motion.

**QUADRANT 4 SYSTEM CORP**

**Bankruptcy Proceedings** On Jan. 24, 2018, Co.'s official committee of unsecured creditors filed with the U.S. Bankruptcy Court an objection to the Debtors' motion to modify its agreement with TriZetto. The committee asserts, "Although it is paraded as a simple contract amendment, Debtors' Motion seeks to settle material claims between Debtors and TriZetto by allowing TriZetto to buy itself out of its obligations under its license agreement with Debtors and any claims Debtors may have against TriZetto. Looked at another way, this amounts to a sale of Debtors' most significant remaining assets to TriZetto. The relief requested effectively eliminates any hope unsecured creditors have of a meaningful recovery while simultaneously trampling on Committee's statutory right to examine TriZetto under its pending Bankruptcy Rule 2004 Motion. Although the Motion purports to settle all issues between the parties, it completely glosses over these disputes, and instead seem to assert that it is within Debtors' business judgment to settle all issues with TriZetto for anything above \$0. As for the significant issues raised in the Debtors' unpursued 2004 examination, Debtors' apparently don't know and aren't going to investigate further. Debtors have to do more to justify the settlement proposed in the Motion, including in particular the full release given to TriZetto, given the claims they raised in their 2004 examination. As it stands, the Motion should be denied without prejudice, and the Committee should be afforded the opportunity to undertake a comprehensive examination of TriZetto, as further detailed in the Committee 2004 Motion."

**QUADRANT 4 SYSTEM CORP**

**Bankruptcy Proceedings** On Jan. 25, 2018, the U.S. Bankruptcy Court approved Co.'s motion to extend the exclusive period during which Co. can file a Chapter 11 plan and solicit acceptances thereof through and including Feb. 6, 2018. As previously reported, "This is Q4's second request and Stratitudes's first request for extension of the Exclusivity Periods. Notwithstanding the requested maintenance of exclusivity, the Debtors anticipate that any plan or plans it will file in the Chapter 11 Cases will be proposed jointly with the Committee. Since their respective Petition Dates, the Debtors' attention has been singularly focused on

selling substantially all their assets efforts that have paid off for their creditors by generating a large pool of money for their estates and for the benefit of both secured (e.g., paying down a large portion of the secured debt) and unsecured creditors (e.g., assumption and assignment of leases and executory contracts, and assumption of certain employee claims). The respective directors, officers and management of the Debtors overlap significantly. Stratitudes' assets served as collateral for Q4's secured lenders. The Chapter 11 Cases were filed in less than ideal circumstances as a result of the Criminal Action, the SEC Action, and the action of the Criminal Defendants. These actions have required additional time and effort on the Debtors' part to complete their Schedules and Statement of Financial Affairs, and have generally complicated the fact-gathering process for many of the motions filed and presented as of Jan. 25, 2018."

**QUANTERIX CORP****Annual Report****Consolidated Income Statement, Years Ended Dec. 31**

(\$000):

	2016	2015
Product revenue.....	10,601	9,477
Service & other revenue.....	5,012	2,515
Collaboration & license revenue.....	1,972	188
Total revenues.....	17,585	12,180
Cost of product revenue.....	6,299	5,661
Cost of services & other revenue.....	3,163	804
Cost of license revenue, related party.....	375	...
Research & development.....	16,993	10,083
Selling, general & administrative expense.....	12,466	10,155
Total operating expenses.....	39,296	26,703
Income (loss) from operations.....	(21,711)	(14,523)
Interest expense, net.....	1,298	1,040
Other (expense) income, net.....	(164)	(380)
<b>Net income (loss).....</b>	<b>(23,173)</b>	<b>(15,943)</b>
Accretion of preferred stock to redemption value.....	4,437	4,355
Accrued dividends on preferred stock.....	8	...
Net income (loss) attributable to common stockholders.....	(27,618)	(20,298)
Weighted average shares outstanding - basic.....	2,143	1,813
Weighted average shares outstanding - diluted.....	2,143	1,813
Year end shares outstanding.....	2,315	1,977
Net income (loss) per share - basic.....	\$(12.89)	\$(11.19)
Net income (loss) per share - diluted.....	\$(12.89)	\$(11.19)
Total number of employees.....	122	...
Number of stockholders.....	75	...

<sup>1</sup> Including related party activity - Product revenue: \$509,000;

<sup>2</sup> Including related party activity - Product revenue: \$527,000;

<sup>3</sup> Including related party activity - Service and other revenue: \$107,000;

<sup>4</sup> Including related party activity - Service and other revenue: \$93,000;

<sup>5</sup> Including related party activity - Collaboration and license revenue: \$172,000;

<sup>6</sup> Including related party activity - Collaboration and license revenue: \$188,000;

<sup>7</sup> Including related party activity - Cost of product revenue: \$322,000;

<sup>8</sup> Including related party activity - Cost of product revenue: \$415,000;

<sup>9</sup> As of September 30, 2017; <sup>10</sup> As is; <sup>11</sup> As of October 31, 2017;

<sup>12</sup> Approximately

**Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):**

	2016	2015
Cash & cash equivalents.....	29,671	2,323
Accounts receivable.....	3,917	2,262
Raw materials.....	563	330
Work-in-process.....	304	198
Finished goods.....	661	474
Inventory.....	1,528	1,002

Prepaid expenses & other current assets.....	127	133
Total current assets.....	35,243	5,720
Laboratory & manufacturing equipment.....	1,937	1,680
Office furniture & equipment.....	657	563
Computers & software.....	451	283
Leasehold improvements.....	133	133
Property & equipment, gross.....	3,178	2,659
Less: Accumulated depreciation.....	1,955	1,579
Property & equipment, net.....	1,223	1,080
Other non-current assets.....	651	551
Total assets.....	37,117	7,351
Accounts payable.....	2,549	1,346
Accrued compensation & benefits.....	1,693	1,546
Accrued inventory.....	70	184
Accrued royalties.....	544	154
Accrued professional services.....	396	372
Accrued development costs.....	843	218
Accrued other.....	533	416
Other accrued expenses.....	2,386	1,344
Deferred revenue.....	3,428	1,474
Current portion of long term debt.....	899	2,078
Total current liabilities.....	10,955	7,788
Preferred stock warrant liability.....	2,802	5,547
Deferred revenue, net of current portion.....	328	1,363
Long-term debt, net of current portion.....	212	200
Other long-term liabilities.....	9,344	7,648
Total liabilities.....	23,641	22,546
Series A redeemable convertible preferred stock.....	28,979	23,898
Series B redeemable convertible preferred stock.....	17,459	15,178
Series C redeemable convertible preferred stock.....	36,678	34,369
Series D redeemable convertible preferred stock.....	45,469	...
Common stock.....	2	2
Retained earnings (accumulated deficit).....	(115,111)	(88,642)
Total stockholders' equity.....	(115,109)	(88,640)

<sup>1</sup> Including from related parties - Accounts receivable: \$124,000; <sup>2</sup> Including from related parties - Accounts receivable: \$63,000; <sup>3</sup> Including to related parties - Accounts payable: \$8,000; <sup>4</sup> Including to related parties - Accounts payable: \$13,000; <sup>5</sup> Including to related parties - Other accrued expenses: \$516,000; <sup>6</sup> Including to related parties - Other accrued expenses: \$94,000; <sup>7</sup> Including to related parties - Deferred revenue: \$1,204,000; <sup>8</sup> Including to related parties - Deferred revenue: \$394,000; <sup>9</sup> Including to related parties - Deferred revenue (long-term): \$149,000; <sup>10</sup> Including to related parties - Deferred revenue (long-term): \$1,226,000

**Recent Dividends:****1. Quanterix Corp common.**

No dividends paid.

**Annual Dividends:****1. Quanterix Corp common.**

No dividends paid.

**RAPID7 INC**

**Offering** On Jan. 23, 2018, Co. announced the pricing of an underwritten public offering of 5,180,000 shares of its common stock at a price to the public of \$22.00 per share. Of the shares being offered, 1,500,000 are being offered by Co. and the remaining 3,680,000 shares are being offered by existing stockholders.

Certain of such existing stockholders have granted the underwriters a 30-day option to purchase up to an additional 770,000 shares of common stock in the offering at the public offering price. The gross proceeds to Co. from the offering, before underwriting discounts and commissions and offering costs, are expected to be \$33,000,000. Co. intends to use the net proceeds from the proposed offering for working capital and general corporate purposes. The offering is expected to close on or about Jan. 30, 2018, subject to satisfaction of customary closing conditions.

#### REAL INDUSTRY INC

**Bankruptcy Proceedings** On Jan. 23, 2018, Co.'s ad hoc equity security holders' committee filed with the U.S. Bankruptcy Court an objection to Co.'s post-petition financing motion. The committee asserts, "This Objection relates to the revised DIP Order approving the increased obligations and the failure to provide for appropriate oversight by and for the parties in interest in the Real Industry case in the revised DIP order. This was a concern raised at the hearing. The Debtor has given notice and ceded certain oversight of the transactions in the DIP Order solely to the Real Alloy creditors and Creditors' Committee, none of which have an interest in the Real Industry assets, financing or restructuring. The petitions for Co.'s parent company and the Real Alloy operating entities were each filed with the same consolidated list of creditors none of which are creditors of Real Industry. Moreover, the revised DIP Order treats the Creditors' Committee as the only legitimate representative of Co.'s estate interests. The Ad Hoc Committee requests that the Debtor makes the following changes to the DIP Order: (a) the reference to the appointment of the Creditors' Committee formation and retention of professional in the Recitals should be deleted; (b) the carve out should apply only to committee appointed in Co.'s cases or acting solely for the constituents of Co.; (c) all notices required to be given to the Borrower should be given to a committee appointed in Co.'s cases; (d) future notice should be given to Real Industry equity holders as the Court directs pursuant to Federal Rule of Bankruptcy Procedure 2002(d); (e) no funds from Co.'s DIP can be used to pay restructuring costs of the Real Alloy debtors." Also on Jan. 23, 2018, the U.S. Bankruptcy Court issued an order approving Co.'s new proposed D.I.P. lenders and a new commitment letter. As previously reported, "After filing the DIP Financing Motion, Co. received an unsolicited offer for alternative postpetition financing from 210 Capital, and the Private Credit Group of Goldman Sachs Asset Management, (collectively, '210/GSAM'). 210/GSAM has, subject to Court approval, agreed to provide Real Industry with a postpetition credit facility (the '210/GSAM Proposed DIP Financing') on terms that are either identical, or materially superior, to the terms of the GSC Proposed DIP Financing. The improved terms offered by the 210/GSAM Proposed DIP Financing include, (i) an improved equity commitment (from \$10,000,000 to \$17,500,000), (ii) increased availability under the proposed post-petition financing facility (from \$4,000,000 to \$5,500,000), (iii) a reduced interest rate (from 12 percent to 11 percent), (iv) the addition of a commitment to provide a \$500,000,000 acquisition financing facility on terms to be negotiated, (v) a reduced upfront fee (from \$300,000 to \$200,000), (vi) a reduced break-up fee (from \$450,000 to \$300,000), and (vii) relaxed case milestones."

#### REAL INDUSTRY INC

**Bankruptcy Proceedings** On Jan. 19, 2018, Co.'s subsidiary, Real Alloy Intermediate Holding, LLC ("Real Alloy") Debtors closed the transactions under which their debtor-in-possession (DIP) financing (the "RA DIP Financing") will be provided. The RA DIP Financing is comprised of (i) up to \$85,000,000 in new money senior secured priming and super-priority post-petition debtor-in-possession notes issued by Real Alloy and guaranteed by RAIH and the other Real Alloy Debtors (the "New Money DIP Notes"), (ii) an additional series of senior secured priming and super-priority post-petition debtor-in-possession notes issued by Real Alloy and guaranteed by RAIH and the other Real Alloy Debtors in the aggregate principal amount of \$170,000,000 (the "Roll Up DIP Notes") in exchange for \$170,000,000 of 10.00% Senior Secured Notes Due 2019 of Real Alloy (the "RA Notes"), and (iii) up to \$110,000,000 in borrowing by certain of the Real Alloy Debtors under a senior secured priming and super-priority post-petition financing in the form of a revolving credit facility. The Real Alloy Debtors' entry into RA FIP Financing was approved by the Bankruptcy Court by final order on Jan. 17, 2018. The Amended and Restated Note Purchase Agreement (the "A&R NPA") was entered into and became effective on Jan. 19, 2018, by and among Real Alloy as issuer, RAIH and certain Real Alloy subsidiaries as guarantors (the "NPA Guarantors"), and the lenders party thereto (the "Purchasers"). The A&R NPA revised certain terms of the Note Purchase Agreement dated Nov. 21, 2017, to among other things: (a) designate Cortland Capital Market Services LLC, as agent (the "Roll-Up Notes Agent") in connection

with the Roll-Up DIP Notes issued under the Indenture dated Jan. 8, 2015, as amended by the Third Supplemental Indenture, (b) included customary provisions to accommodate the Roll-Up Notes Agent's role as agent in connection with the Roll-Up DIP Notes, and (c) update the Existing NPA and accompanying schedules to reflect factual changes that occurred since the Bankruptcy Court entered a debtor-in-possession order on Nov. 20, 2017 in response to the voluntary petitions of relief under Chapter 11 of the Bankruptcy Code entered by the Real Alloy Debtors (the "Interim Order"). Fees paid by the Real Alloy Debtors in connection with the A&R NPA included (a) a closing fee equal to 1.5% of principal outstanding to all Purchasers in the aggregate (less, in the case of certain holders of the RA Notes, an amount equal to the 1.5% of the closing fee paid on a portion of their commitments under the Existing NPA) and (b) certain other customary agent fees. As previously disclosed, interest on the New Money DIP Notes accrues at a rate of 11.50% per annum, with an additional 2.00% per annum during the continuance of an event of default, payable monthly. The Third Supplemental Indenture was entered into and became effective on Jan. 19, 2018, among Real Alloy, RAIH and the NPA Guarantors as guarantors, Wilmington Trust, National Association, as trustee and collateral trustee for the RA Notes issued under the Indenture and the Roll-Up Notes Agent (the "Third Supplemental Indenture"). The Third Supplemental Indenture further amended the Indenture. Pursuant to the Third Supplemental Indenture, Real Alloy issued the Roll-Up DIP Notes in an aggregate principal amount of \$170,000,000, in exchange for RA Notes in the aggregate principal amount of \$170,000,000 tendered to the Roll-Up Notes Agent and subsequently cancelled. As previously disclosed, interest on the Roll-Up DIP Notes accrues at a rate of 10.00% per annum, payable upon maturity or default. Repayment and prepayment of any principal of the Roll-Up DIP Notes can be made without a premium or penalty. The Third Supplemental Indenture was also revised to make express reference to the New Money DIP Notes.

#### REAL INDUSTRY INC

**Bankruptcy Proceedings** On Jan. 25, 2018, Co. filed with the U.S. Bankruptcy Court a notice of filing of exhibits to the Final DIP Credit Agreement. The notice states, "Exhibit 1 is the execution version of the DIP Credit Agreement (the 'Final DIP Credit Agreement'). Exhibit 2 is a redline comparing the Final DIP Credit Agreement with the Original DIP Credit Agreement." The amendment notes, "Equity Commitment" means the commitment of the Equity Commitment Parties set forth in the Commitment Letter to purchase Borrower's common stock in an amount which equals a percentage between 45% or 49% of Borrower's total outstanding common stock for a purchase price of \$17,500,000, as set forth in the Commitment Letter. The cash balance of Borrower shall be no less than \$950,000 'DIP Commitment' means, with respect to DIP Lenders' commitment to lend hereunder, \$5,500,000 in the aggregate as set forth on the Commitment Annex, as such amount may be reduced pursuant to the terms of this DIP Credit Agreement or the DIP Order."

#### REAL INDUSTRY INC

**Bankruptcy Proceedings** On Jan. 22, 2018, the Bankruptcy Court entered a final order, the Order (I) Authorizing Real Industry, Inc. to Obtain Senior Secured, Superpriority, Postpetition Financing, (II) Granting Liens and Providing Superpriority Administrative Expense Status, (III) Modifying the Automatic Stay in Connection Therewith, (IV) Authorizing Real Industry, Inc. to Obtain the Equity Commitment, and (V) Granting Related Relief (the 210 DIP Order), approving Co. to enter into a senior-secured, superpriority debtor-in-possession credit facility in an aggregate principal amount of \$5,500,000 (the 210 DIP Facility) with 210 Capital, LLC or an affiliate thereof (210 Capital) and the Private Credit Group of Goldman Sachs Asset Management, L.P. or one or more of their managed funds or accounts (GSAM), and together with 210 Capital, the Lenders). Co. previously described the 210 DIP Facility in its Current Report on Form 8-K, filed on Jan. 17, 2018 (the Jan. 17 Form 8-K). The 210 DIP Facility applies only to Co., and not the Real Alloy Debtors, who have their separate DIP financing, as previously disclosed. The 210 DIP Order authorized, among other things, Co. to (i) enter into the Credit Agreement (as defined below), related agreements securing and guaranteeing the 210 DIP Facility, and other ancillary agreements (collectively, such agreements, the DIP Documents) with the Lenders and certain non-Debtor subsidiaries of Co.; (ii) use the 210 DIP Facility in accordance with the proposed budget provided in connection with the 210 DIP Order and 210 DIP Facility, as updated with the Lenders from time to time (the Budget); (iii) obtain the commitment of the Lenders as set forth in the commitment letter of the Lenders (as previously disclosed in the Jan. 17 Form 8-K, the 210 Commitment Letter) regarding the purchase of 45-49% of the outstanding common stock of Co. for a purchase price of

\$17,500,000 (the Equity Commitment); and (iv) pay all fees, interest, expenses and indemnities provided in the 210 DIP Documents and related to the 210 DIP Facility, including the Upfront Fee (as defined below), a \$300,000 cash payment and issuance of up to 4.9% of the Company's outstanding common stock as a break-up fee if the Equity Commitment is terminated by Co. without Lenders consent (together, the Break-Up Fee), and the reasonable fees of Lenders counsel, advisors and consultants in connection with the 210 DIP Facility. The 210 DIP Order grants the Lenders superpriority administrative claims under the Bankruptcy Code, all liens provided in the DIP Documents, and priority of repayment in the event of any additional financing by Co.; provided, however, that the 210 DIP Order provides, and the Lenders have agreed, that any proceeds from the sale of the Real Alloy Debtors assets distributed to Co. in the Chapter 11 Proceedings shall, after repayment of all outstanding 210 DIP Facility obligations in full, be distributed to the existing stakeholders of Co. in accordance with the priority scheme in the Bankruptcy Code and not distributed to Lenders by any other means (including in respect of any equity of the Lenders from the Equity Commitment or the Break-Up Fee). Further, the 210 DIP Order approved the previously disclosed milestones related to the 210 DIP Facility and Equity Commitment, in each case to be satisfied satisfactorily to Lenders, including: (i) Co.'s filing, in each case in form satisfactory to Lenders, of a plan of reorganization in the Chapter 11 Proceedings (the Plan of Reorganization) and related disclosure statement (such disclosure statement, the Disclosure Statement) with the Bankruptcy Court on or before Feb. 16, 2018; (ii) entry of an order by the Bankruptcy Court approving the Disclosure Statement on or before Mar. 29, 2018 (subject to court availability); (iii) the parties execution of definitive documents related to the Equity Commitment no later than five days prior to the hearing of the Bankruptcy Court to consider confirmation of the Plan of Reorganization; (iv) entry of the Confirmation Order on or before May 1, 2018 (subject to court availability); and (v) Co.'s satisfaction of all conditions to consummate the Plan of Reorganization no later than ten days after the entry of the Confirmation Order. The Bankruptcy Court approved Co.'s borrowing of up to \$4,000,000 of the 210 DIP Facility pursuant to the terms of the DIP Documents upon entry of the 210 DIP Order (the Initial Loans), and approved Co.'s borrowing of the \$1,500,000 balance of the 210 DIP Facility on or after Jan. 31, 2018 to the extent no party in interest files an objection to the increase from the originally contemplated \$4,000,000 amount of the DIP facility by such date.

#### REAL INDUSTRY INC

**Bankruptcy Proceedings** On Jan. 26, 2018, Co. filed with the U.S. Bankruptcy Court a notice of filing of final third supplemental indenture and note purchase agreement for Real Alloy Debtors, with the following exhibits: Exhibit 1: execution version of the third supplemental indenture; Exhibit 2: redline comparing the final third supplemental indenture with the original third supplemental indenture; Exhibit 3 is an execution version of the Amended and restated senior secured super-priority DIP note purchase agreement, the Final NPA; Exhibit 4: redline comparing the Final NPA with the Original NPA. The amendment in agreement notes, "Section 2.03 of the Indenture is hereby amended by replacing subsections (a) through and including (d) in their entirety to read as follows: (a) The Trustee shall authenticate and make available for delivery (or, in the case of the Roll-Up Notes, record in the applicable Register) upon a written order of the Issuer signed by one Officer (an 'Authentication Order') (i) Notes for original issue on the date hereof in an aggregate principal amount of \$305,000,000 and (ii) subject to the terms of this Indenture, Additional Notes in an aggregate principal amount to be determined at the time of issuance and specified therein. Such Authentication Order shall specify the amount of the Notes to be authenticated, the date on which the original issue of Notes is to be authenticated and whether the Notes are to be Initial Notes or Additional Notes. Notwithstanding anything to the contrary in this Indenture, any issuance of Additional Notes after the Issue Date shall be in a principal amount of at least \$2,000. Pursuant to Section 2.01 of the Indenture, as amended hereby, Co. hereby creates and issues a series of Notes designated as '10.000% Senior Secured Second Priority Notes' in the aggregate principal amount of \$170,000,000 (the 'Roll-Up Notes')." According to the final NPA, "German Factoring Facility" means the factoring facility between Real Alloy Germany and the Factoring Facility Purchaser under the Factoring Facility Documents with a maximum financing amount of 50,000,000."

#### REAL INDUSTRY INC

**Bankruptcy Proceedings** On Jan. 29, 2018, Co. filed with the U.S. Bankruptcy Court a monthly operating report for Dec. 2017. For the month, the total combined Debtors reported a \$4,200,000 net loss on gross revenue of \$48,100,000; net sales

of \$45,900,000; \$323,446 in professional fees and \$1,500,000 in selling, general and administrative expenses. Total Debtors' cash at the beginning of the month was \$9,600,000 and \$8,400,000 at month's end, with net cash flow of \$1,200,000 and cash disbursements of \$49,900,000 on \$40,100,000 in cash receipts.

#### REAL INDUSTRY INC

**Bankruptcy Proceedings** On Jan. 30, 2018, Co. filed with the U.S. Bankruptcy Court an amended contracts schedule. The notice states, "Pursuant to the Bidding Procedures Order, the Debtors are required to file a schedule (the 'Contracts Schedule') listing all of the Real Alloy Debtors' executory contracts and unexpired leases (the 'Contracts'), including the amounts that the Debtors believe are necessary to assume the Contracts (the 'Cure Amounts'). An amended Contracts Schedule (the 'Amended Contracts Schedule'), which replaces the Original Contracts Schedule in its entirety, is Exhibit A."

#### RF INDUSTRIES LTD.

##### Annual Report

##### Consolidated Income Statement, Years Ended Oct. 31 (\$):

	2017	2016	2015
		(revised)	(revised)
Net sales	30,964,000	30,241,000	30,908,000
Cost of sales	22,242,000	21,778,000	20,446,000
Gross profit (loss)	8,722,000	8,463,000	10,462,000
Engineering expenses	845,000	747,000	775,000
Selling & general expenses	7,506,000	9,560,000	8,888,000
Goodwill & other intangible asset impairment	...	2,844,000	...
Total operating expenses	8,351,000	13,151,000	9,663,000
Operating income (loss)	371,000	(4,688,000)	799,000
Other income	29,000	5,000	35,000
Income (loss) from continuing operations before provision for income taxes	400,000	(4,683,000)	834,000
Current provision (benefit) for federal income taxes	400,000	(332,000)	300,000
Current provision (benefit) for state income taxes	24,000	(13,000)	4,000
Total current provision (benefit) for income taxes	424,000	(345,000)	304,000
Deferred provision (benefit) for federal income taxes	(293,000)	(179,000)	(126,000)
Deferred provision (benefit) for state income taxes	3,000	(128,000)	(38,000)
Total deferred provision (benefit) for income taxes	(290,000)	(307,000)	(164,000)
Provision (benefit) for income taxes	134,000	(652,000)	140,000
Income (loss) from continuing operations	266,000	(4,031,000)	694,000
Income (loss) from discontinued operations, net of tax	116,000	(58,000)	300,000
<b>Net income (loss)</b>	<b>382,000</b>	<b>(4,089,000)</b>	<b>994,000</b>
Weighted average shares outstanding - basic	8,840,895	8,786,510	8,494,111
Weighted average shares outstanding - diluted	8,915,764	8,786,510	8,862,217
Year end shares outstanding	8,872,246	8,835,483	8,713,664
Net earnings (loss) per share - continuing operations - basic	\$0.03	\$(0.46)	\$0.08
Net earnings (loss) per share - discontinued operations - basic	\$0.01	\$(0.01)	\$0.04
Net earnings (loss) per share - diluted	\$0.03	\$(0.46)	\$0.08
Net earnings (loss) per share - diluted	\$0.04	\$(0.47)	\$0.11
Number of full time employees	195	189	...
Number of common stockholders	315	196	...

	2017	2016	2015
		(revised)	(revised)
Cash & cash equivalents	6,039,000	5,258,000	...
Trade accounts receivable, gross	3,974,000	4,139,000	...
Less: allowance for doubtful accounts	73,000	62,000	...
Trade accounts receivable, net	3,901,000	4,077,000	...
Raw materials & supplies	2,520,000	2,642,000	...
Work in process	194,000	279,000	...
Finished goods	3,395,000	3,101,000	...
Inventories, net	6,109,000	6,022,000	...
Prepaid taxes	20,000	871,000	...
Prepaid expense	526,000	347,000	...
Notes receivable	83,000	83,000	...
Other current assets	115,000	135,000	...
Other current assets	744,000	1,436,000	...
Total current assets	16,793,000	16,793,000	...
Equipment & tooling	3,302,000	3,203,000	...
Furniture & office equipment	871,000	799,000	...
Property & equipment, gross	4,173,000	4,002,000	...
Less accumulated depreciation	3,462,000	3,174,000	...
Total property & equipment	711,000	828,000	...
Goodwill	3,219,000	3,219,000	...
Amortizable intangible assets, net	3,030,000	3,619,000	...
Non-amortizable intangible assets	1,237,000	1,237,000	...
Other assets	70,000	141,000	...
Total assets	25,060,000	25,837,000	...
Accounts payable	1,356,000	1,138,000	...
Wages payable	855,000	941,000	...
Accrued receipts	695,000	578,000	...
Earn-out liability	236,000	707,000	...
Other current liabilities	456,000	544,000	...
Total current liabilities	3,598,000	3,908,000	...
Deferred tax liabilities	119,000	409,000	...
Other long-term liabilities	...	128,000	...
Total liabilities	3,717,000	4,445,000	...
Common stock	89,000	88,000	...
Additional paid-in capital	19,654,000	19,379,000	...
Retained earnings (accumulated deficit)	1,600,000	1,925,000	...
Total stockholders' equity	21,343,000	21,392,000	...

□ Restated to reflect the shutdown of the Bioconnect division as discontinued operations

##### Consolidated Balance Sheet, Years Ended Oct. 31 (\$):

	2017	2016
		(revised)
Cash & cash equivalents	6,039,000	5,258,000
Trade accounts receivable, gross	3,974,000	4,139,000
Less: allowance for doubtful accounts	73,000	62,000
Trade accounts receivable, net	3,901,000	4,077,000
Raw materials & supplies	2,520,000	2,642,000
Work in process	194,000	279,000
Finished goods	3,395,000	3,101,000
Inventories, net	6,109,000	6,022,000
Prepaid taxes	20,000	871,000
Prepaid expense	526,000	347,000
Notes receivable	83,000	83,000
Other current assets	115,000	135,000
Other current assets	744,000	1,436,000
Total current assets	16,793,000	16,793,000
Equipment & tooling	3,302,000	3,203,000
Furniture & office equipment	871,000	799,000
Property & equipment, gross	4,173,000	4,002,000
Less accumulated depreciation	3,462,000	3,174,000
Total property & equipment	711,000	828,000
Goodwill	3,219,000	3,219,000
Amortizable intangible assets, net	3,030,000	3,619,000
Non-amortizable intangible assets	1,237,000	1,237,000
Other assets	70,000	141,000
Total assets	25,060,000	25,837,000
Accounts payable	1,356,000	1,138,000
Wages payable	855,000	941,000
Accrued receipts	695,000	578,000
Earn-out liability	236,000	707,000
Other current liabilities	456,000	544,000
Total current liabilities	3,598,000	3,908,000
Deferred tax liabilities	119,000	409,000
Other long-term liabilities	...	128,000
Total liabilities	3,717,000	4,445,000
Common stock	89,000	88,000
Additional paid-in capital	19,654,000	19,379,000
Retained earnings (accumulated deficit)	1,600,000	1,925,000
Total stockholders' equity	21,343,000	21,392,000

##### Recent Dividends:

##### 1. RF Industries Ltd. common.

ExDate	Amt	Declared	Record	Payable
12/29/2014	0.07	11/20/2014	12/31/2014	01/15/2015

ExDate	Amt	Declared	Record	Payable
03/27/2015	0.07	03/12/2015	03/31/2015	04/15/2015
06/26/2015	0.07	06/09/2015	06/30/2015	07/15/2015
09/28/2015	0.07	09/08/2015	09/30/2015	10/15/2015
12/29/2015	0.07	12/18/2015	12/31/2015	01/15/2016
03/29/2016	0.02	03/03/2016	03/31/2016	04/15/2016
06/28/2016	0.02	06/08/2016	06/30/2016	07/15/2016
09/28/2016	0.02	09/08/2016	09/30/2016	10/15/2016
12/28/2016	0.02	12/09/2016	12/31/2016	01/17/2017
03/29/2017	0.02	03/09/2017	03/31/2017	04/15/2017
06/28/2017	0.02	06/09/2017	06/30/2017	07/14/2017
09/28/2017	0.02	09/08/2017	09/30/2017	10/15/2017
12/28/2017	0.02	12/14/2017	12/31/2017	01/15/2018

##### Annual Dividends:

##### 1. RF Industries Ltd. common.

2015	0.28	2016	0.13	2017	0.08
2018	0.02				

##### RIGNET INC

**Acquisition Development** On Jan. 17, 2018, Co. announced that it has agreed to acquire Intelie Solues em Informatica SA, a real-time, predictive analytics company that is an award-winning, early pioneer in deep machine learning and planning optimization. The transaction is anticipated to close in Q1 2018, subject to customary closing conditions. Terms of the transaction were not disclosed.

##### ROCKET PHARMACEUTICALS INC

**Offering** On Jan. 23, 2018, Co. announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of \$13.25 per share. The gross proceeds to Rocket from the offering are expected to be \$72,875,000 before deducting the underwriting discounts and commissions and other estimated offering expenses. Rocket has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock. All the shares in the offering are to be sold by Co. The offering is expected to close on or about Jan. 26, 2018, subject to satisfaction of customary closing conditions. Co. intends to use the net proceeds from this offering to fund the continued development of its pipeline of gene therapies for rare diseases, enhancements to in-house manufacturing, and general corporate purposes.

##### SANMINA CORP

**Annual Meeting Development** On Jan. 24, 2018, Co. announced that its Annual Meeting of Stockholders will be held on Mar. 5, 2018, at 11:00 a.m., Pacific Standard Time, at Co.'s corporate offices, located at 30 E. Plumeria Drive, San Jose, CA, 95134.

##### SCIENTIFIC GAMES CORP

**Acquisition Completed** On Jan. 23, 2018, Co. acquired Tech Art, the gaming industry's supplier of hole-card readers for blackjack. Terms of the transaction were not disclosed.

##### SPARK ENERGY INC

**Secondary Offering** On Jan. 23, 2018, Co. announced the pricing of a public offering of 2,000,000 shares of its 8.75% Series A Fixed-to-Floating Rate Cumulative Redeemable Perpetual Preferred Stock ("Series A Preferred Stock") at a public offering price of \$25.25. The underwriters have been granted a 30-day option to purchase up to 250,000 additional shares of Series A Preferred Stock from Spark, exercisable in whole or in part, at the public offering price less the underwriting discount. The offering is scheduled to close on Jan. 26, 2018.

##### STARBUCKS CORP.

**Annual Meeting Development** On Jan. 26, 2018, Co. scheduled its Annual Meeting of Shareholders for Mar. 21, 2018 at 10:00 a.m. (Pacific Time), at the Seattle Center, located at 321 Mercer Street, in Seattle, WA.

##### STITCH FIX INC

##### Annual Report

	07/29/17	07/30/16
Revenue, net	977,139	730,313
Costs of goods sold	542,718	407,064
Gross profit	434,421	323,249
Selling, general & administrative expense	402,781	259,021
Income (loss) from operations	31,640	64,228
Remeasurement of preferred stock warrant liability	18,881	3,019
Other income, net	42	13
Income (loss) before provision for income taxes	12,801	61,222

Current federal income taxes	17,027	29,204
Current state income taxes	3,096	4,706
Current income taxes	20,123	33,910
Deferred federal income taxes	(6,009)	(5,458)
Deferred state income taxes	(719)	(411)
Deferred income taxes	(6,728)	(5,869)
Provision for income taxes	13,395	28,041
<b>Net income (loss)</b>	(594)	33,181
Less: noncumulative dividends to preferred stockholders	...	2,533
Less: undistributed earnings to participating securities	...	22,437
Net income (loss) attributable to common stockholders	(594)	8,211
Weighted average shares outstanding - basic	24,974	22,730
Weighted average shares outstanding - diluted	24,974	27,883
Year end shares outstanding	26,835	25,873
Net earnings (loss) per share - basic	\$(0.02)	\$0.36
Net earnings (loss) per share - diluted	\$(0.02)	\$0.34
Total number of employees	5,800	...

□ As is; □ As of July 29, 2017

#### Consolidated Balance Sheet, Years Ended (\$000):

	07/29/17	07/30/16
Cash	110,608	91,488
Restricted cash	250	1,391
Inventory, net	67,592	44,808
Prepaid expenses & other current assets	19,312	10,585
Total current assets	197,762	148,272
Computers equipment	5,086	3,440
Office furniture & equipment	4,514	2,341
Leasehold improvements	14,693	6,974
Capitalized software	11,481	6,443
Construction in progress	1,618	4,199
Total property & equipment, gross	37,392	23,397
Less accumulated depreciation & amortization	10,659	4,246
Property & equipment, net	26,733	19,151
Deferred tax assets	19,991	13,201
Restricted cash, net of current portion	9,100	8,613
Other long-term assets	3,619	2,363
Total assets	257,205	191,600
Accounts payable	44,238	36,588
Compensation & benefits	9,632	7,673
Inventory purchases	11,186	6,302
Advertising	9,995	2,831
Sales taxes	3,702	2,646
Shipping & freight	3,390	4,517
Property & equipment	...	1,656
Other accrued liabilities	8,458	4,348
Accrued liabilities	46,363	29,973
Preferred stock warrant liability	26,679	7,798
Gift card liability	5,190	3,197
Deferred revenue	7,150	4,431
Other current liabilities	4,298	3,086
Total current liabilities	133,918	85,073
Deferred rent	11,781	9,541
Other long-term liabilities	7,423	4,817
Total liabilities	153,122	99,431
Convertible preferred stock	42,222	42,222
Common stock	1	...

Additional paid-in capital	27,002	10,938
Retained earnings (accumulated deficit)	34,858	39,009
Total stockholders' equity	61,861	49,947

#### Recent Dividends:

1. **Stitch Fix Inc class B common.**  
No dividends paid.

2. **Stitch Fix Inc class A common.**  
No dividends paid.

#### Annual Dividends:

1. **Stitch Fix Inc class B common.**  
No dividends paid.

2. **Stitch Fix Inc class A common.**  
No dividends paid.

#### STITCH FIX INC

Earnings, 3 mos. to (Consol. - \$000):

	10/28/17	10/29/16
Total Revenues	295,563	236,004
Cost & expenses	286,019	209,476
Operating income	9,544	26,528
Other income (expense), net	9,088	(1,496)
Net before taxes	18,632	25,032
Income taxes	5,144	11,789
<b>Net income</b>	13,488	13,243
Balance for common	3,915	3,595
Earnings common share		
Primary	\$0.15	\$0.15
Fully Diluted	\$0.04	\$0.14
Common Shares:		
Full Diluted	33,262	28,940
Year-end	26,835	...

#### Consolidated Balance Sheet Items, as of (\$000):

	2017	2016
Assets:	2017	2016
Cash & equivalents	131,096	87,576
Inventories	87,576	235,506
Current assets	235,506	29,545
Net property & equip.	29,545	298,711
Total assets	298,711	...
Liabilities:	158,971	78,267
Current liabilities	158,971	78,267
Stockholders' equity	78,267	76,535
Net current assets	76,535	...

#### SYNOLOGIC INC

**Offering** On Jan. 23, 2018, Co. announced the pricing of its underwritten public offering of 5,130,000 shares of its common stock at a public offering price of \$9.75 per share. The gross proceeds to Co. from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Co., are expected to be \$50,017,500. All shares of common stock to be sold in the offering are being sold by Co. In addition, Co. has granted to the underwriters a 30-day option to purchase up to 769,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about Jan. 26, 2018, subject to the satisfaction of customary closing conditions.

#### TETRA TECH INC

**Acquisition Completed** On Jan. 25, 2018, Co. acquired Bridgnet International Inc. ("BridgeNet"). BridgeNet is an aviation technology solutions firm based in Newport Beach, California, that is focused on aerospace data analytics, environmental and acoustic consulting, and 3-dimensional airspace visualization for federal and commercial aviation customers. Terms of the transaction were not disclosed.

#### TETRA TECH INC

**Acquisition Development** On Jan. 17, 2018, Co. announced that it has signed a definitive agreement to acquire Norman Disney & Young (NDY), a leader in sustainable infrastructure engineering design. Terms of the transaction were not disclosed.

#### TETRA TECH INC

**Annual Meeting Development** On Jan. 24, 2018, Co. announced that its Annual Meeting of Stockholders will be held on Mar. 8, 2018, at 10:00 a.m. Pacific Time at the Westin Pasadena, 191 N. Los Robles Avenue, Pasadena, CA, 91101.

#### TINTRI INC

Earnings, 9 mos. to Oct 31(Consol. - \$000):

	2017	2016
Total Revenues	96,993	84,349
Net Sales	71,474	64,316
Cost & expenses	211,180	160,853

Operating income	(114,187)	(76,504)
Interest expense	6,242	4,044
Other income (expense), net	585	735
Net before taxes	(119,844)	(79,813)
Income taxes	428	440
<b>Net income</b>	(120,272)	(80,253)
Balance for common	(100,524)	(80,253)
Earnings common share		
Primary	\$(6.33)	\$(23.52)
Fully Diluted	\$(6.33)	\$(23.52)
Common Shares:		
Full Diluted	15,873	3,412
Year-end	31,324	...

#### ULTRAGENYX PHARMACEUTICAL INC

**Secondary Offering** On Jan. 22, 2018, Co. announced the pricing of its underwritten public offering of 4,385,965 shares of its common stock at a price to the public of \$57.00 per share, resulting in gross proceeds of \$250,000,000 before underwriting discounts. In addition, Co. has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 657,895 shares of Co.'s common stock at the public offering price, less the underwriting discount.

#### VIACOM INC

**Annual Meeting Development** On Jan. 22, 2018, Co. scheduled its annual Meeting of Shareholders for Friday, Mar. 8, 2018, at 9:00 a.m., EST, at Co.'s Corporate Headquarters, 1515 Broadway, NY, New York.

#### WALGREENS BOOTS ALLIANCE INC

**Acquisition Completed** On Jan. 18, 2018, Rite Aid Corp. sold 625 stores and related assets to Co.'s wholly-owned subsidiary, Walgreen Co., for cash proceeds of \$1,309,800,000.

#### WOODWARD, INC.

Earnings, 3 mos. to Dec 31(Consol. - \$000):

	2017	2016
Net Sales	470,148	442,894
Cost & expenses	432,661	395,835
Operating income	37,487	47,059
Net before taxes	37,487	47,059
Income taxes	19,227	511
<b>Net income</b>	18,260	46,548
Earnings common share		
Primary	\$0.30	\$0.76
Fully Diluted	\$0.29	\$0.73
Common Shares:		
Full Diluted	63,709	63,671
Year-end	61,254	61,401

#### Consolidated Balance Sheet Items, as of (\$000):

	2017	2016
Assets:	2017	2016
Cash & equivalents	85,779	503,523
Inventories	503,523	979,242
Current assets	979,242	930,158
Net property & equip.	930,158	2,725,174
Total assets	2,725,174	...
Liabilities:	353,120	583,339
Current liabilities	353,120	583,339
Long-term debt	583,339	1,400,546
Stockholders' equity	1,400,546	626,122
Net current assets	626,122	...

#### XILINX, INC.

Earnings, 9 mos. to (Consol. - \$000):

	12/30/17	12/31/16
Total Revenues	1,866,142	1,739,877
Cost & expenses	1,309,285	1,209,944
Operating income	555,289	525,990
Other income (expense), net	(1,513)	(2,588)
Net before taxes	564,427	519,860
Income taxes	217,705	50,773
<b>Net income</b>	346,722	469,087
Earnings common share		
Primary	\$1.39	\$1.86
Fully Diluted	\$1.34	\$1.74
Common Shares:		
Full Diluted	258,995	269,182
Year-end	254,815	248,935

#### XTANT MEDICAL HOLDINGS INC

**Special Meeting of Stockholders** On Jan. 22, 2018, Co. scheduled its Special Meeting of Stockholders on Feb. 13, 2018, at 10:00 a.m. Eastern Standard Time, at 112 South Tryon Street, 2nd Floor, Charlotte, North CA 28284.

\*

*MERGENT OTC INDUSTRIAL News Reports 0027-0865* is published weekly online on Tuesdays and printed the last Friday of the month by Mergent, Inc., 444 Madison Ave., New York, NY 10022. The News Reports are part of the OTC INDUSTRIAL Manual and provide periodic updates. Send address changes to MERGENT OTC INDUSTRIAL, 580 Kingsley Park Drive, Fort Mill, SC 29715.

Copyright©2018 by Mergent. All information contained herein is copyrighted in the name of Mergent, Inc., and none of such information may be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed or resold, or stored for subsequent use for any such purpose, in whole or in part, in any form or matter or by any means whatsoever, by any person without Mergent's prior written consent.

All information contained is obtained by Mergent, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error, as well as other factors, however, such information is provided "as is", without warranty of any kind. NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY INFORMATION IS GIVEN OR MADE BY MERGENT IN ANY FORM OR MANNER WHATSOEVER. Under no circumstances shall Mergent have any liability to any person or entity for (a) any loss or damage in whole or in part caused by, resulting from, or relating to, any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analyzing, editing, transcribing, transmitting, communicating or delivering any such information, or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if Mergent is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, any such information.